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Kettlewell found that in unpolluted areas, more of his light-colored moths had 
survived. In soot-blacked areas, more of the dark-colored moths had survived. 
Thus Kettlewell showed that in each environment the moths that were better 
camouflaged had the higher survival rate. It was logical to conclude that when 
soot darkened the tree trunks in the area, natural selection caused the dark-
colored moths to become more common. Today Kettlewell’s work is considered to 
be a classic demonstration of natural selection in action.  























HNPCC versus sporadic microsatellite-unstable colon 
cancers follow different routes toward loss of HLA class I 
expression
BMC Cancer, 2007; 7:33.
MUTYH-associated polyposis carcinomas frequently lose 
HLA class I expression - a common event amongst DNA-
repair-deficient colorectal cancers
Journal of Pathology, 2009; 219: 69-76.
Infiltration of Lynch colorectal cancers by activated 
immune cells associates with early staging of the primary 
tumor and absence of lymph node metastases
Clinical Cancer Research, 2009; 18: 1237-1245.
Frameshift truncating mutations in TGFBR2 are reverted 
by transcriptional slippage in colorectal cancer
Manuscript submitted.
Role of the microenvironment in the tumourigenesis of 
microsatellite unstable and MUTYH-associated polyposis 
colorectal cancers
Mutagenesis 2012; 23(2): 247-53.






























Microsatellite instability - high
Natural killer
Transforming growth factor beta





1.1. Epidemiology and etiology of 
colorectal cancer
Colorectal cancer is the third most 
frequently diagnosed cancer and the fourth 
most common cause of cancer-related deaths 
worldwide. Its incidence is estimated at 17.2 
per 100,000 individuals, although higher 
prevalence is observed in the so-called 
“developed countries” (1). The overall five-
year survival rate for colorectal cancer is 
higher than 50% but the individual patient 
prognosis is highly dependent on tumor-
staging at diagnosis (2, 3). For instance, 
patients affected by localized lesions 
(stages 0 and I) present five-year survival 
rates higher than 90% (2). The majority of 
colorectal cancers (approximately 95%) 
arise in a sporadic context, while autosomal 
dominant and recessive cancer syndromes 
are responsible for the remainder (Figure 
1). Nevertheless, familial aggregation 
of colorectal cancers, not explained by 
known cancer syndromes, is observed in 
approximately one-third of the so-called 
“sporadic cases” (4). The identification of 
genetic predisposition factors in these families 
constitutes one of the major remaining 
challenges in colorectal cancer research (5, 
6). Tobacco smoking, high intake of saturated 
fat and red meat, and alcohol consumption 
constitute major environmental factors that 
have been associated with an increased risk 
for colorectal cancer (7).
1.2. Genetics of oncogenesis
Colorectal cancer is a heterogeneous 
disease where different oncogenic pathways 
can support cancer development (8, 9). 
Classically, colorectal cancers have been 
divided according to the type of genetic 
instability that is observed in tumors 
(Figure 2). Extensive accumulation of 
nucleotide insertions and deletions at DNA 
microsatellite sequences (short nucleotide 
repeats) are observed in 15-20% of colorectal 
cancers. Such phenotype, denominated 
microsatellite instability-high (MSI-H), 
is caused by a defective DNA mismatch 
repair system (10, 11). Almost invariably, 
MSI-H sporadic colorectal cancers display 
DNA hypermethylation of the MLH1 gene 
promoter, thereby silencing its expression, 
as well as widespread methylation of gene 
promoters throughout the genome (10, 11). 
Lynch syndrome, previously denominated 
hereditary non-polyposis colorectal cancer 
(HNPCC) syndrome, is the hereditary 
counterpart of MSI-H colorectal cancers 
and affects carriers of germline mutations in 
mismatch repair genes, where MLH1, MSH2, 
MSH6, and PMS2 are most commonly 
affected. Lynch syndrome is an autosomal 
dominant genetic condition where one 
defective allele of a mismatch repair gene is 
inherited. Cancer development in carriers 
generally involves the somatic inactivation 
of the second copy of the gene (10, 11). The 
mismatch repair system is a caretaker of 
the genome that is essential for the repair 
of nucleotide mismatches and small base 
insertions and deletions (12). Microsatellite 
DNA sequences are hotspots for the 
accumulation of mutations, resulting from 
the frequent slippage of DNA polymerases 








Figure 1. Spectrum of colorectal cancers according to 
their etiology (FAP - Familial Adenomatous Polyposis 




from the formation of loop DNA structures 
in single stranded microsatellites and 
from inefficient proofreading exonuclease 
activity by the DNA polymerase (14, 15). 
Large chromosomal aberrations are rare 
in MSI-H colorectal cancers and their cells 
generally possess peridiploid DNA contents, 
similar to the one of a healthy somatic cell 
(16). MSI-H colorectal cancers develop 
more frequently in the colon ascendens 
and are further characterized by a poorly 
differentiated and mucinous histology and a 
dense intraepithelial, lymphocytic infiltrate 
(8, 17, 18).
Most colorectal cancers (80-85%) are 
mismatch repair proficient and do not 
display microsatellite instability (MSI). 
Instead, the majority of microsatellite 
stable colorectal cancers present gross 
chromosomal aberrations that translate 
into aneuploid DNA contents in tumor cells 
(19). Recurrent chromosomal aberrations 
in colorectal cancer include gains of 
chromosomes 7, 8q, 13, and 20q and losses 
of 4q, 8p, and 18q (20-22). The generation 
of chromosomal instability (CIN) has been 
associated with the loss of function of the 
Adenomatous Polyposis Coli (APC) gene, 
a classical tumor suppressor in colorectal 
cancer (23). Truncating mutations in APC 
occur in the majority of colorectal cancers 
with CIN and are considered to be one of the 
Figure 2. Simplified scheme representing the most frequent (epi-) genetic alterations occurring during colorectal 












































initiating events in colorectal tumorigenesis 
(24, 25). APC is part of a protein complex 
that controls the availability of b-catenin, 
a key signal transducer of the canonical 
Wnt signaling (26). Loss of APC promotes 
the stabilization and nuclear accumulation 
of b-catenin that, upon association with 
specific transcription factors, activates the 
transcription of proto-oncogenes such as 
MYC and CCND1 (26, 27). APC defects were 
also shown to disturb kinetochore function 
and chromosomal segregation during 
mitosis, thereby supporting APC’s role in 
the propagation of CIN (23). Activation of 
Wnt signaling has also been suggested to 
promote the so-called stemness of cancer 
cells that, thereby, can overcome replicative 
senescence (28, 29). Germline mutations in 
APC cause familial adenomatous polyposis 
(FAP), an autosomal dominant disease that is 
responsible for less than 1% of all colorectal 
cancers (30). Although common, truncating 
somatic mutations in APC are less frequent in 
MSI-H colorectal cancers when compared to 
tumors with CIN (31). Interestingly, MSI-H 
colorectal cancers, particularly the ones 
associated with Lynch syndrome, display 
relatively frequent mutations in the b-catenin 
gene (CTNNB1) (31, 32). Such mutations 
were suggested to increase the stability of 
b-catenin and, thereby, to produce an effect 
similar to the loss of APC (33). Although 
alterations in the Wnt signaling pathway 
constitute a hallmark in colorectal cancer 
development, biallelic inactivation of APC 
or activating mutations in CTNNB1 are only 
present in approximately 80% of tumors. 
The comprehensive characterization of the 
genomic landscape of colorectal cancers 
identified less frequent mutation targets such 
as SOX9, TCF7L2, AXIN2, FBXW7, ARID1A, 
and FAM123B, which, cumulatively, might 
explain Wnt activation in the remaining 
proportion of cases (24).
Another form of (epi-) genetic instability 
can be recognized in a subset of colorectal 
cancers and it refers to the widespread 
methylation of CpG islands at gene promoters 
(34). The CpG island methylator (CIMP) and 
the MSI phenotypes are largely overlapping 
but CIMP-positive, MSI-negative tumors 
still account for approximately 8% of 
colorectal cancers (35). Of note, in a sporadic 
context, CpG methylation changes, often 
accompanied by mutations in BRAF, are 
considered to precede the onset of MSI (36). 
Furthermore, CIN can accompany CIMP 
in a substantial proportion of cases (37, 
38). Interestingly, a fraction of colorectal 
cancers simultaneously lack CIN, MSI, and 
CIMP (37). The type of genetic instability 
observed in different tumors has been shown 
to correlate with the patients’ survival and 
response to therapy. An improved patient 
prognosis has been associated with the MSI 
phenotype, while worse patient survival 
was reported for CIMP-positive tumors 
that lacked MSI (37, 39). Paradoxically, 
MSI colorectal cancers appear to be less 
sensitive to fluorouracil (5-FU), the standard 
chemotherapeutic adjuvant in colorectal 
cancer therapy (40, 41).
In addition to FAP and Lynch syndrome, 
a number of other cancer syndromes are 
responsible for the onset of colorectal cancer 
in a hereditary setting. MUTYH-associated 
polyposis (MAP) constitutes the only known 
colorectal cancer syndrome that is inherited 
in a recessive manner. It is caused by germline 
mutations in the gene that encodes for the 
MUTYH DNA glycosylase (42). Although 
MAP patients display a milder phenotype 
than FAP patients, most carriers of biallelic 
mutations in MUTYH develop numerous 
polyps at a young age that, eventually, 
progress to malignant lesions (42). The 
MUTYH protein is part of the DNA base-
excision repair pathway and is involved in the 
repair of one of the most common forms of 
oxidative damage, the oxidation of guanine 
to 8-oxo-7,8-dihydro-2’-deoxyguanosine 
(8-oxoG). In the absence of MUTYH, cells 
display a distinctive mutation signature that 
is characterized by the abundance of G:C 
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to T:A transversions, which results from 
the mispairing of 8-oxoG with adenines 
during replication (43). Similar to MSI-H 
cancers, MAP patients were reported to 
have better overall survival than sporadic 
colorectal cancer patients (44). Furthermore, 
MAP tumors most often develop in the 
proximal colon and frequently present 
mucinous histologies and high amounts of 
intraepithelial lymphocytic infiltrate (45).
A number of human syndromes have been 
associated with the finding of hamartomatous 
and/or hyperplastic polyps in affected 
individuals (46). However, for several of 
those, the “a priori” risk for colorectal cancer 
development is unknown. On the other hand, 
the risk for colorectal cancer has been clearly 
assessed in the autosomal dominant Peutz-
Jeghers syndrome (PJS) and in the juvenile 
polyposis syndrome (JPS), which are caused 
by germline mutations in the STK11/LKB1 
gene and the BMPR1A or SMAD4 genes, 
respectively (47). Although mutations in 
BMPR1A and SMAD4 explain a considerable 
proportion of juvenile polyposis cases, the 
genetic basis of disease is still elusive in a 
large number of patients. It was recently 
established that patients suffering from 
the PTEN hamartoma tumor syndrome, 
comprising Cowden and Bannayan-Riley-
Rubalcaba syndromes, are also at increased 
risk for colorectal cancer (48). Finally, a 
recent whole genome sequencing approach 
identified high-penetrance variants that 
confer susceptibility to colorectal polyposis 
and cancer in the POLE and POLD1 genes 
(49). Those variants were located in the 
proofreading domains of the polymerases 
and compromised the repair of mismatches 
introduced during DNA replication.
1.3. Mutation landscape of MSI-H and 
MAP colorectal cancers
MSI-H colorectal cancers are notorious 
for the accumulation of insertions and 
deletions at microsatellite DNA sequences 
throughout the genome. Accordingly, genes 
containing microsatellite repeats within 
their coding regions are often targeted by 
mutations in those tumors. The TGFBR2 
and ACVR2A genes, which contain ten and 
eight adenine microsatellites, respectively, 
are found mutated in the majority of MSI-H 
colorectal cancers (50-52). Interestingly, the 
MSH3 and MSH6 mismatch repair genes also 
carry microsatellite sequences within their 
sequences that are targeted by MSI (24). This 
secondary targeting of mismatch repair genes 
constitutes an additional source of DNA 
repair deficiency that contributes to the high 
mutation load of MSI-H cancers (53-55). 
Similar to the inactivation of the APC gene, 
the constitutional activation of the MAPK 
signaling pathway is one of the primary 
events in colorectal cancer tumorigenesis. It 
occurs mainly through the establishment of 
activating mutations in the KRAS GTPase 
or the BRAF serine/threonine kinase 
(Figure 2), in a mutually exclusive manner 
(56). Mutations in the BRAF gene are most 
frequent in sporadic MSI-H cancers and 
absent in Lynch-associated cancers (57, 58). 
In turn, mutations in the KRAS gene are more 
common in colorectal cancers with CIN and 
the ones developing in patients with Lynch 
syndrome (Figure 2) (59-61). As discussed 
previously, in addition to their hypermutated 
genomes, most MSI-H sporadic cancers 
display a methylator phenotype, responsible 
for the altered expression of a myriad of 
genes (Figure 2) (24).
The majority of MAP carcinomas display 
mutations in the APC and KRAS genes that 
are postulated to derive directly from the 
MUTYH-associated, base-excision repair 
deficiency (62). G>T transversions at GAA 
triplets are frequent in APC and nearly all 
KRAS mutations found in MAP carcinomas 
are restricted to a c.34 G>T transversion, an 
uncommon substitution in the remaining 
spectrum of colorectal cancers. Mutations in 
TP53 and SMAD4 are also encountered in a 








but are not restricted to G>T transversions, 
suggesting that they might occur at a later 
stage in tumorigenesis (45). In agreement 
with the fact that the base-excision repair 
system is not directly involved in the repair 
of small insertions and deletions, MSI is 
rarely observed in MAP carcinomas (45, 
62). Interestingly, MAP tumors display a 
distinctive form of chromosomal instability 
characterized by the widespread presence 
of chromosomal copy-neutral loss of 
heterozygosity (63).
2. TGF-b SIGNALING PATHWAY: A 
MULTIFACETED REGULATOR OF 
CARCINOGENESIS
The transforming growth factor-b 
(TGF-b) signaling pathway regulates cell 
proliferation, differentiation, apoptosis 
and migration (64). Abnormalities in this 
pathway compromise tissue homeostasis 
and may support carcinogenesis (65, 66). 
Signal transduction is initiated with the 
binding of a TGF-b ligand to the TGF-b type 
2 transmembrane serine/threonine kinase 
receptor TGFbR2, which becomes activated 
and phosphorylates the type 1 TGF-b serine/
threonine kinase receptor TGFbR1 (67). A 
type 3 TGF-b receptor (TGFbR3) facilitates 
the interaction between TGF-b ligands 
and the serine/threonine kinase receptors 
(Figure 3) (68). Upon activation, TGFbR1 
phosphorylates a receptor-regulated Smad 
(Smad2, Smad3) that forms a heterocomplex 
with the co-Smad, Smad4, in the cytoplasm 
(Figure 3) (69, 70). This complex translocates 
to the nucleus where it modulates the 
expression of gene targets together with 
additional transcription factors (Figure 
3) (71). Alternative ligands (e.g. Activins) 
and receptors (e.g. ACVR2A, ALK4) can 
also convey TGF-b signaling to Smad2 
and Smad3 (70). The bone morphogenetic 
protein (BMP) pathway operates in an 
analogous way to TGF-b but makes use of 
different ligands, receptors, and intracellular 
Smad proteins, except for Smad4, which 
operates as a co-Smad in both the TGF-b and 
BMP pathways (69).
As discussed previously, the TGFBR2 and 
ACVR2A genes are fated to mutate in MSI-H 
colorectal cancers due to the presence of 
microsatellite repeats within their protein-
Figure 3. The TGFb signaling pathway (adapted from Meulmeester et al. (72)). The molecules more often affected by 












































coding sequences (50-52). Mutations often 
target both alleles and result in frameshifted, 
early-truncated proteins that are unable to 
transduce TGF-b signaling. Mutations in 
TGF-b receptor genes are uncommon in 
microsatellite stable tumors that instead 
target the Smad proteins, most often Smad4. 
The SMAD4 gene is found mutated in up 
to 15% of microsatellite stable colorectal 
cancers and its locus (18q21.1) is targeted 
by loss of heterozygosity in the majority of 
CIN colorectal cancers (21, 73, 74). Since 
the SMAD2 gene is located in the same 
chromosomal region, it is also affected by 
loss of heterozygosity. Mutations in SMAD2 
and SMAD3 occur in a minority of colorectal 
cancers (75).
Disruption of the TGF-b pathway leads 
to the decreased expression of TGF-b 
target genes such as the cell cycle regulators 
CDKN1A (p21) and CDKN2B (p15), 
thereby providing a growth advantage to 
tumor cells (76, 77). Accordingly, loss of 
SMAD4 expression has been associated with 
advanced disease stages and poor prognosis 
in colorectal cancer patients (78, 79). On the 
other hand, a dual role has been attributed 
to TGF-b in the sense that activation of 
this pathway might also promote malignant 
behavior. High levels of TGF-b ligand 
at primary tumors were correlated with 
metastatic disease and tumor recurrence 
in colorectal cancer (80, 81). Furthermore, 
TGF-b production by cancer cells was 
shown to dampen anti-tumor immune 
responses and to promote the colonization 
of tumor metastasis through its activity on 
stromal cells (82, 83). By acquiring defects in 
TGF-b signalling mediators, tumor cells can 
modulate their microenvironment through 
TGF-b production without suffering from its 
growth suppressive effects. 
3. TUMOR IMMUNOLOGY
3.1. The immune system: unable but 
equipped?
Cancer development is accompanied 
by massive changes at cellular and tissue 
level that, theoretically, could be detected 
and dealt with by the immune system. 
Nevertheless, reports on immune system-
mediated, spontaneous tumor rejections, in 
humans, are scarce. As most cancer-related 
deaths occur after reproductive age, and are 
thus not involved in natural selection, the 
contribution of this disease for the shaping 
of the immune system is considered to be 
limited. Nevertheless, both the innate and 
adaptive immune systems are equipped 
with mechanisms to detect and eliminate 
anomalous cells. Moreover, the increased 
risk for malignancies in patients receiving 
immune suppressants partially supports 
a role for the immune system as a tumor 
suppressor (84). It should be noted, however, 
that the use of immune suppressants 
also impairs the clearing of infections by 
oncogenic viruses and thus, the increased 
cancer risk observed in these patients is not 
exclusively attributable to an impaired anti-
tumor immune response. 
The genetic and epigenetic alterations 
that occur in cancer cells lead to changes 
in their protein repertoire that include the 
production of mutated proteins and the 
abrogation of proteins that would normally 
be expressed in their non-transformed 
counterparts. The former may constitute 
novel antigens for which central T cell 
tolerance was not imposed (85). They could 
trigger anti-tumor immune responses that 
would eventually lead to the destruction of 
cancer cells (“non-self recognition”) (86, 
87). The activation of anti-tumor immune 
responses requires the uptake of tumor 
antigens by professional antigen presenting 
cells such as dendritic cells (Figure 4). The 
high turnover of cancer tissues guarantees 








also of molecular “danger signals” that are 
essential for dendritic cell activation (88). 
Upon activation, dendritic cells migrate 
to tumor-draining lymph nodes where 
they induce proliferation and activation of 
antigen-specific CD4+ and CD8+ T cells 
(Figure 4). The activation of CD8+ T cells 
occurs through the presentation of antigens 
by Human Leukocyte Antigen (HLA) class I 
molecules (cross-presentation) while antigen 
presentation to CD4+ T cells is mediated by 
HLA class II molecules (89). Once activated, 
CD8+ T cells acquire cytotoxic capacity 
and the ability to eliminate cancer cells that 
express the same tumor antigen that led to 
their activation. The killing of tumor cells may 
occur through the release of lytic granules by 
cytotoxic CD8+ T cells (CTLs) that contain 
the pore-forming protein Perforin and 
Granzyme A and B proteases but also by 
the Fas-FasL cell death pathway, provided 
that tumor cells express the Fas receptor (90, 
91). Expression of HLA class I molecules by 
tumor cells is an essential condition for the 
recognition of tumor antigens by CTLs (92, 
93).
In addition to their role in presenting “non-
self ” antigens to immune cells, HLA class I 
molecules are fundamental for recognition 
of the “self ”. Their absence from the cell 
surface (“missing-self ”) evokes the action of 
natural killer (NK) cells, another lymphocyte 
with cytotoxic potential (94, 95). HLA class 
I molecules constitute ligands for NK cell 
receptors that contain immunoreceptor 
tyrosine-based inhibitory motifs (ITIMs) at 
their cytoplasmic tail. These motifs become 
phosphorylated upon HLA class I binding 
and subsequently suppress NK cell activation 
(96). In addition, activating signals are 
also required to trigger NK cell-mediated 
cytotoxicity, generally transduced by the 
NKG2D receptor at NK cells. Those signals 
are provided by ligands such as MICA, MICB 
or ULBP, which are upregulated in target 
cells as a consequence of cellular stress (97-
99). It is considered that the balance between 
inhibitory and activation signals provided by 
target cells ultimately determines the action 
of NK cells. 
The combination of T cell-mediated 
recognition of tumor antigens and the 
detection of anomalous cells by NK 
lymphocytes could constitute effective anti-
tumor barriers. In support of this, recognition 
of tumor antigens by autologous T cells has 
been widely demonstrated in cancer patients 
(100, 101), while a variety of tumors have 
been shown to express NK cell-activating 
ligands (102, 103). Thus, not surprisingly, the 
presence of tumor-infiltrating immune cells 
constitutes a relevant prognostic indicator in 
cancer patients (104, 105). Remarkably, Galon 
and colleagues discovered that qualitative 
and quantitative profiles of immune cell 
infiltration in colorectal cancer were better 
prognostic indicators than tumor staging, 
although a potential overrepresentation of 
MSI-H tumors in the study cohort was not 
accounted for (106). The presence of high 
numbers of tumor-infiltrating lymphocytes 
has generally been associated with 
improved clinical outcomes in colorectal 
cancer patients (107). Reports were most 
concordant when analyzing specifically the 
infiltration by cytotoxic T cells expressing 
granzyme B (108, 109), suggesting a major 
role for antigen-driven anti-tumor immune 
response. The potential role of other T cell 
subsets such as regulatory T cells (Tregs) 
in the progression of colorectal cancer has 
not been clearly established (107). As for 
NK cells, they are relatively infrequent in 
colorectal cancer tissues but the expression 
of NKG2D ligands in cancer cells has been 
associated with improved patient prognosis 
(103, 110). NK cells appear to be particularly 
important in controlling tumor metastases 
by eliminating circulating tumor cells in the 
blood stream (111, 112).
3.2. Immune escape: too fast, too furious
The mechanisms underlying cancer cell 
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Figure 4. Dendritic cells play a central role in mediating anti-tumor immune responses. The high cellular turnover 
of tumor tissues guarantees an abundant source of tumor antigens for dendritic cells. After picking up the antigens 
and transporting them to the draining lymph nodes, dendritic cells activate naïve CD4+ and CD8+ T cells through 
the presentation of HLA/antigen complexes. CD8+ T cell activation occurs through HLA class I while CD4+ T cell 
activation is mediated by HLA class II. Additional co-stimulatory signals are required for T cell activation and are 
provided by the interaction between B7 ligands present on antigen presenting cells and the CD28 receptor on T cells. 





























resilience to the action of the immune system, 
also in the context of immunotherapy, have 
been a major object of study for tumor 
immunologists throughout the years. Anti-
tumor immune responses constitute strong 
vectors of selection that contribute towards 
the shaping of clonal evolution in cancer. 
One of the most common and functionally 
interpretable immune evasive mechanisms is 
the loss of HLA class I expression by tumors. 
By losing HLA class I expression, cancer 
cells are excused from presenting tumor 
antigens to CTLs, thereby avoiding detection 
and destruction (113). Furthermore, loss 
of HLA class I is also expected to result in 
failure of therapeutic approaches based on 
CD8+ T cell recognition such as vaccination 
with tumor antigens or adoptive transfer of 
autologous T cells (114). On the other hand, 
abrogation of HLA class I expression would 
support NK cell-mediated recognition in 
the presence of activating signals and thus, 
further escape mechanisms are expected 
to accompany HLA class I loss (115, 116). 
Cellular stress, such as the one derived 
from DNA damage, was shown to result in 
increased expression of NK cell activating 
ligands (117). Therefore, and providing that 
DNA damage response mechanisms are in 
place, tumor cells should upregulate the 
expression of NK cell activating ligands as 
a consequence of their chronic exposure to 
replicative damage and/or chromosomal 
instability. Not surprisingly, a considerable 
proportion of human cancers lack NKG2D 
ligands and are, thereby, resistant to NK 
cell-mediated lysis, even when HLA class 
I expression is abrogated (103, 118, 119). 
Absent or low expression of NKG2D ligands 
has been generally correlated with increased 
malignant behavior of tumors (103, 120, 
121), but conflicting findings underline the 
complexity of anti-tumor immunity (122, 
123). An additional escape mechanism to NK 
cells is provided by the release of soluble forms 
of NKG2D ligands by tumor cells, which 
induce the internalization and destruction of 
NKG2D, thereby impairing NK cell function 
(124). Furthermore, acquired expression of 
the non-classical HLA-G antigen and the 
loss of HLA class II expression have also 
been reported in cancer cells (125, 126). As 
a corollary of the accumulated evidence on 
the selection of immune evasive traits during 
cancer progression, Douglas Hanahan 
and Robert A. Weinberg have recently 
acknowledged immune escape as a hallmark 
of cancer in an updated version of their 
seminal review (127). The aforementioned 
phenotypes are conceptually concordant with 
Darwinian models of evolution that imply 
the elimination of “less-fit” tumor clones 
(128). The generation of clonal diversity is 
fundamental for the emergence of immune 
escape phenotypes and other traits. The 
latter is assured by the impairment of DNA 
repair and damage response mechanisms 
that support the accelerated evolutionary 
process that accompanies tumorigenesis. 
Nevertheless, there is a high probability that 
carcinogenic processes not always lead to the 
generation of tumor variants with immune 
evasive properties and that, occasionally, 
tumors are indeed swiftly eliminated by the 
immune system in asymptomatic individuals.
3.3. HLA genes and the HLA class I antigen 
presenting pathway
The HLA system is the human counterpart 
of the major histocompatibility complex 
(MHC), a unifying feature in vertebrate 
organisms that plays a key role in the 
immune system. The MHC class I and class II 
loci are comprised of the most polymorphic 
genes known in vertebrates in spite of the 
strong selective pressure imposed by the 
evolutionary “arms race” between hosts 
and pathogens. Instead, a positive selection 
is in place for the maintenance of MHC 
variability, derived from the fact that the 
immune system has to deal with a myriad of 
pathogens (129).
The HLA class I molecule is a heterodimer 
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consisting of a variable heavy chain (a) and 
the non-polymorphic b2-microglobulin 
molecule, encoded by a gene located on 
chromosome 15. Three loci encode for 
different HLA class I heavy-chains on 
chromosome 6p: HLA-A, HLA-B and HLA-C. 
These are generally defined as the classical 
HLA class I genes for which more than 
5000 alleles are currently known (130). The 
HLA-E, HLA-F and HLA-G genes comprise 
the non-classical HLA class I genes, which 
are considerably less polymorphic than the 
classical HLA class I genes. Their proteins are 
not involved in general antigen presentation 
but, instead, they bind peptides derived 
from the classical HLA class I molecules 
themselves (131). Similar to the classical HLA 
class I molecules, they can also modulate NK 
cell activity (132). HLA class II molecules 
are composed of two variable chains (a and 
b), encoded by six main HLA class II genes 
also located on chromosome 6p: HLA-DPA1, 
HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-
DRA and HLA-DRB (130). 
Each HLA class I (classical) or class II 
allelic variant is able to present a pool of 
peptides that display affinity to that specific 
allele. This affinity is defined by anchor 
residues located at the extremities of a 
peptide sequence that directly bind the HLA 
molecule. Since the sequences within anchor 
residues are relatively free to vary, each HLA 
class I molecule can present a broad range 
of peptides (133). Cross-presentation-apart, 
the peptides presented in the context of 
HLA class I are derived from endogenous 
proteins that have either reached the end 
of their functional life or resulted from 
defective transcription or translation 
(Figure 5). Those peptides are generated in 
the cytosol by the 26S proteasome which 
is composed of a 20S core barrel protein 
complex with protease activity, sandwiched 
by two 19S caps (134). The LMP2 (PSMB9), 
LMP7 (PSMB8) and LMP10 (PSMB10) 
proteins are core subunits of the 20S complex 
in the immunoproteosome, a modified 
proteasome form that is particularly effective 
in generating peptides for HLA class I in 
the presence of inflammatory signals (135). 
Recently, the cytosolic endopeptidases 
nardilysin and TOP were also shown to 
complement the proteosome’s activity and 
to be essential for the generation of specific 
CTL epitopes (136). In order to be loaded 
onto HLA class I molecules, peptides 
must be transported by the transporter 
associated with antigen processing (TAP) 
proteins TAP1 and TAP2 into the lumen 
of the endoplasmic reticulum (Figure 5). 
The TAP proteins associate with HLA class 
I molecules through their interaction with 
Tapasin, a HLA class I chaperone. Additional 
chaperones such as Calnexin, Calreticulin 
and ERp57 are involved in stabilizing HLA 
class I and in assisting the loading of peptides 
onto this molecule (137). Often, peptides 


























reticulum before loading onto HLA class I. 
This task is performed by the ERAP1 and 
ERAP2 aminopeptidases (138). Since the 
peptides generated by the 26S proteasome 
are highly unstable in the cytosol, only a 
small fraction of those reach the cell surface 
in complex with HLA class I (Figure 5) (139). 
The HLA class II antigen presenting pathway 
deals with peptides derived from exogenous 
proteins that are processed by endocytic 
pathways (134). 
3.4. The HLA system: around the dogmas
Traditionally, HLA class I molecules have 
been considered to be expressed on nearly 
every nucleated cell of the human body, 
except for few “immune privileged” sites (e.g. 
brain, cornea, liver, and testis). However, a 
number of studies support that additional 
tissues present non-detectable or reduced 
HLA class I expression (115, 140, 141). We 
(de Miranda and Morreau, unpublished), 
and others (142), have also observed that 
HLA class I expression is often higher 
in colorectal cancers than in the normal 
mucosa, which might derive from an overall 
increase in protein expression in tumors or 
from a natural response to cellular stress. 
Therefore, in certain contexts, the lack of 
HLA class I expression in tumors might not 
represent a loss but rather the inability of 
tumor cells to induce HLA class I expression. 
Nevertheless, since normal colorectal tissue 
consistently displays immune-reactivity to 
anti-HLA class I antibodies, we refer to HLA 
class I loss throughout the thesis.
In the opposite direction, there is a 
generalized misconception that HLA 
class II expression is restricted to antigen-
presenting cells such as B cells, dendritic 
cells and macrophages. On the contrary, 
HLA class II expression can be induced in 
a variety of cells including epithelial cells, 
endothelial cells, and fibroblasts in the 
presence of inflammatory signals (143, 144). 
Additionally, a variety of tumors have been 
shown to acquire expression of HLA class 
II molecules during tumorigenesis (126, 
145, 146). These observations are of great 
relevance as HLA class II molecules are 
known to mediate the presentation of tumor-
specific antigens (147, 148). Local activation 
of CD4+ T cells at tumor sites might support 
a more effective CTL response (149) but also 
the triggering of Th1 and Th2 inflammatory 
responses that engage macrophages and 
eosinophils, respectively (150). Furthermore, 
a subset of CD4+ T cells appears to possess 
cytotoxic capacity and the ability to eliminate 
target cells presenting tumor antigens in a 
MHC class II context (151, 152).
4. OUTLINE OF THE THESIS
In this thesis, we compiled five studies 
where we report some of the genetic and 
molecular alterations that accompany the 
tumorigenesis of mismatch repair and 
MUTYH deficient colorectal cancers, 
with particular focus on immune escape 
mechanisms. 
Both sporadic and hereditary mismatch 
repair deficient colorectal cancers are 
characterized by the presence of a 
conspicuous intraepithelial lymphocytic 
infiltrate, indicative of an anti-tumor 
immune response. We hypothesized that 
those tumors would be particularly prone 
to adopt immune evasive strategies, such 
as the loss of HLA class I expression, in 
order to escape from immune cell-mediated 
recognition and destruction. In chapter 2, 
we studied the expression of HLA class I, and 
associated antigen processing machinery 
molecules, in a well-characterized set of 
sporadic and Lynch colorectal cancers. We 
compared the frequencies of HLA class I 
loss between mismatch repair-deficient and 
proficient colorectal cancers and dissected 
the molecular mechanisms that underlie 
HLA class I defects in sporadic and hereditary 
mismatch repair deficient tumors.
Following the discovery of the MUTYH-
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associated polyposis (MAP) syndrome and 
the reported histopathological similarities 
with mismatch repair deficient tumors, we 
speculated that MAP colorectal cancers 
might also present a high frequency of 
HLA class I alterations. In chapter 3, we 
characterized the expression of HLA class I 
and associated antigen processing machinery 
molecules in a cohort of MAP colorectal 
cancers and compared our findings to the 
ones reported in chapter 2. 
The outgrowth of tumor clones lacking 
HLA class I expression is likely to result from 
the immune system-mediated destruction 
of HLA class I-positive cancer cells. In 
addition to providing an effective immune 
escape mechanism from cytotoxic T cells, 
the loss of this essential immune recognition 
molecule may also alter the capacity of 
cancer cells to invade surrounding tissues 
or to disseminate at distance (metastases). 
In chapter 4, we investigated a potential 
correlation between the type and density of 
lymphocytic infiltration in Lynch colorectal 
cancers with their HLA class I phenotype 
and clinicopathological stage. By relating 
the density of intraepithelial lymphocytic 
infiltrate with distinct HLA class I phenotypes 
we sought to establish a link between the 
agent of selection and the selected traits, 
respectively. 
 In chapter 5, we have studied one of the 
most common genetic alterations found in 
MSI-H colorectal cancers: the accumulation 
of frameshift mutations in the TGFBR2 gene. 
TGFbR2 is a fundamental receptor for the 
transduction of TGF-b signaling in cells. 
Despite the fact that biallelic truncating 
mutations in TGFBR2 occur in the majority 
of MSI-H cancers, some studies have reported 
that TGF-b signaling is still active in these 
tumors. We have attempted to replicate the 
latter findings in a cohort of MSI-H tumors 
and in a panel of colorectal cancer cell lines. 
Furthermore, we provide a mechanistic 
explanation for the retained sensitivity to 
TGF-b observed in TGFBR2 mutants.
The alterations observed in HLA class 
I expression and in TGF-b pathway 
components in colorectal cancers are 
tightly connected to the role of the 
microenvironment in selecting the “most 
fit” tumor phenotypes. In colorectal tumors 
that develop in a background of mismatch or 
base-excision repair deficiency, the relation 
between tumor genotypes, phenotypes, and 
the environmental agents of natural selection 
is particularly evident and fascinating. These 
relations are discussed in a review paper that 
comprises chapter 6.
A few concluding remarks and future 
perspectives are presented in chapter 7.
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Abnormalities in Human Leukocyte 
Antigen (HLA) class I expression are 
common in colorectal cancer. Since HLA 
expression is required to activate tumor 
antigen-specific cytotoxic T-lymphocytes 
(CTL), HLA class I abnormalities represent 
a mechanism by which tumors circumvent 
immune surveillance. Tumors with high 
microsatellite instability (MSI-H) are 
believed to face strong selective pressure 
to evade CTL activity since they produce 
large amounts of immunogenic peptides. 
Previous studies identified the prevalence 
of HLA class I alterations in MSI-H 
tumors. However, those reports did not 
compare the frequency of alterations 
between hereditary and sporadic MSI-H 
tumors neither the mechanisms that led to 
HLA class I alterations in each subgroup.
To characterize the HLA class I expression 
among sporadic MSI-H and microsatellite-
stable (MSS) tumors, and HNPCC tumors 
we compared immunohistochemically 
the expression of HLA class I, β2-
microglobulin (β2m), and Antigen 
Processing Machinery (APM) components 
in 81 right-sided sporadic and 75 HNPCC 
tumors. Moreover, we investigated the 
genetic basis for these changes.
HLA class I loss was seen more frequently 
in MSI-H tumors than in MSS tumors 
(P < 0.0001). Distinct mechanisms were 
responsible for HLA class I loss in HNPCC 
and sporadic MSI-H tumors. Loss of HLA 
class I expression was associated with β2m 
loss in HNPCC tumors, but was correlated 
with APM component defects in sporadic 
MSI-H tumors (P < 0.0001). In about half 
of the cases, loss of expression of HLA class 
I was concordant with the detection of one 
or more mutations in the B2M and APM 
components genes.
HLA class I aberrations are found at 
varying frequencies in different colorectal 
tumor types and are caused by distinct 
genetic mechanisms. Chiefly, sporadic and 
hereditary MSI-H tumors follow different 
routes toward HLA class I loss of expression 
supporting the idea that these tumors 
follow different evolutionary pathways 
in tumorigenesis. The resulting variation 
in immune escape mechanisms may have 
repercussions in tumor progression and 
behavior.
INTRODUCTION
During cancer development, tumor cells 
may elicit cytotoxic T-lymphocyte (CTL)-
mediated immune responses–partly a 
consequence of accumulated gene mutations 
that are translated into altered peptides (1). 
Tumor cell expression of HLA class I-antigen 
complexes is essential for CTL recognition of 
aberrant peptides and subsequent activation 
(2). Consequently, alteration of HLA 
class I cell surface expression provides an 
effective mechanism by which tumors can 
escape immune detection (3,4). Multiple 
mechanisms have been shown to underlie 
defects in HLA class I expression by tumor 
cells. They include mutations in the individual 
HLA class I genes HLA-A, -B and -C, located 
on chromosome 6p21.3) (5); mutations in 
β2-microglobulin (β2m) (6-9), molecule 
required for cell surface expression of HLA 
class I antigens; and defects in components 
of the HLA class I-associated antigen-
processing machinery (APM) (9-11). The 
APM consists of proteasome components 
delta, MB1 and Z; the immunoproteasome 
components LMP2, LMP7 and LMP10; 
peptide transporters TAP1 and TAP2; and 
chaperones Calnexin, Calreticulin, ERp57, 
and Tapasin. The immunoproteasome 
generates peptides mostly, although not 
exclusively from endogenous proteins, TAP1 
and TAP2 facilitate peptide translocation 
from the cytosol into the lumen of the 
endoplasmic reticulum, where the peptides 
are loaded onto the HLA class I molecules 
with the aid from the several chaperones 
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(12).
Chromosomal instability (CIN) and 
microsatellite instability (MIN) are the 
two major forms of genetic instability in 
colorectal cancer. Combined with distinct 
somatic mutation patterns and epigenetic 
modifications, CIN and MIN lead to the 
development of sporadic colorectal cancer 
(13). MIN sporadic tumors, which constitute 
approximately 15% of all colorectal cancer 
cases and up to 40% of the tumors localized 
on the right side (preceding the splenic 
flexure) of the colon (14), have a phenotype 
resulting from the epigenetic inactivation 
of the mismatch repair gene MLH1. Its 
inactivation destroys a cell’s ability to repair 
base-base mismatches and small insertions or 
deletions in repetitive stretches, leading to an 
accumulation of frameshift mutations that get 
translated into abnormal peptide sequences. 
When these mutations are accumulated to 
large extent in the cell genome the tumors are 
said to possess high-microsatellite instability 
(MSI-H) (15). Hence, it is expected that genes 
containing microsatellite sequences within 
their coding regions are more susceptible to 
somatic mutations, as seen in the TGFBR2 
gene. TGFBR2’s third exon contains a 
microsatellite repeat of 10 adenines that is 
frequently targeted by frameshift mutations 
in MSI-H tumors (16). MSI-H is also the 
hallmark of hereditary non-polyposis 
colorectal cancer (HNPCC), in which 
germline mutations of MLH1, MSH2, MSH6 
and PMS2 can be found. HNPCC constitutes 
approximately 2–4% of all CRC cases (17). 
Tumors with MSI-H are thought to be more 
able to stimulate a CTL-mediated immune 
response due to their frequent generation 
of the aberrant frameshift peptides (18). 
Therefore, these tumors are subjected to a 
greater selective pressure which favors the 
outgrowth of tumor cells with the ability to 
escape from recognition and destruction by 
host immune system.
Various studies have identified HLA 
alterations in colorectal cancer (19-21), 
including the prevalence of HLA class I 
alterations in MSI-H tumors (8,22). However, 
the latter studies did not compare the 
frequency of alterations between hereditary 
and sporadic MSI-H tumors neither 
the mechanisms that led to HLA class I 
alterations in each subgroup. It was suggested 
that MSI-H sporadic and hereditary tumors 
follow parallel evolutionary pathways 
during tumorigenesis in terms of both 
genotype and phenotype (23). As far as HLA 
class I defects are concerned it was never 
investigated whether these different tumors 
present distinct escape mechanisms from 
the immune system. In the present study, we 
compared the frequency of defects in HLA 
class I expression in right-sided sporadic 
(MSI-H and microsatellite-stable (MSS) sub-
groups) colon tumors and in HNPCC tumors 
and studied the mechanisms underlying any 
abnormalities in these subgroups.
RESULTS
HLA class I, β2m and APM component 
expression
In order to compare the expression of HLA 
class I in sporadic MSI-H and MSS right 
sided tumors (RST) and HNPCC MSI-H 
cases, we used an antibody panel recognizing 
monomorphic determinants expressed on 
HLA class I heavy chains, β2m and APM 
components (Figure 1).
In total, we identified loss of HLA class I 
expression in about 34.6% of the RST and 
42.7% of the HNPCC cases. The frequency of 
alterations differed significantly between the 
sporadic MSS and MSI-H RST. The lack of 
HLA class I expression was more frequent in 
MSI-H sporadic cases than in MSS cases (P 
< 0.0001), as it was 16.7% in the latter group, 
but 60.6% in the former (Table 1).
Subsequently, we have investigated the 
frequency of a concomitant loss of HLA 
class I expression with that of either the β2m 













sporadic subset, loss of HLA class I expression 
was more often associated with that of one 
of the APM components, occurring in about 
37% of HLA-negative tumors regardless 
of their mismatch repair status (Table 1). 
β2m loss was only found in one HLA class 
I negative MSI-H sporadic tumor (case 65) 
that interestingly also presented loss of the 
APM molecules TAP2, Calreticulin and 
Tapasin (Figure 2). In contrast, loss of HLA 
class I expression in HNPCC cases was more 
frequently associated with that of β2m (Table 
1), as it was found in 46.9% of the HLA class 
I-negative tumors. In contrast loss of any 
APM component was observed in only 6% of 
these cases (h38, h49) which also showed loss 
of β2m expression.
In sporadic RST, the simultaneous loss 
of more than one APM molecule per case 
was frequent (Figure 2). Only 3 out of 10 
cases lost a single APM component. The 
TAP2 molecule was most frequently lost (6 
cases), followed by TAP1, Tapasin and LMP2 
(5 cases), Calreticulin (4 cases), LMP7 (2 
Figure 1. Example of immunohistochemical analysis performed on the RST and HNPCC tumors (Amplification 
10×). A, Positive expression of HLA class I antigens detected with the HCA2 antibody. The epithelial (large arrow) 
membranous expression of HLA class I antigens is identical to the lymphocytic infiltrate (small arrow). B, Loss of 
expression of HLA class I identified with the HCA 2 antibody. The lymphocytic infiltrate (small arrow) was used as a 
positive control to determine the loss of expression on the epithelial cells. C, Loss of expression of β2m in a HNPCC 
case. D, Loss of expression of one of the APM members (Tapasin) in a RST case. 
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RST MSS + 40 0 0
N = 81 N = 48
(59,3%) - 8 (16.7%) 3 (37.5%)* 0
MSI-H + 13 0 0
N = 33
(41,7%) - 20 (60.6%) 7 (35.0%)* 1 (5.0%)*
HNPCC MSI-H + 43 0 0
N = 75
- 32 (42.7%) 2 (6.3%)* 15 (46.9%)*
HLA † APM loss ‡ β2m loss ‡































total 26 1 5 6 5 1 4 1 5 2 0
Figure 2. Loss of expression of β2m and different APM members was detected by immunohistochemistry in the 
RST that presented with HLA loss. The shadowing (in black) is indicative for loss of expression of the respective 
molecules. (tpsn – Tapasin, calnx – Calnexin, crtcln – Calreticulin). 
Table 1. HLA, APM and β2m expression in RST and HNPCC colon cancer.
* – The percentage of cases that lost APM or β2m expression is relative to the number of HLA negative cases of each 
subset, † – HLA expression differs significantly between sporadic MSI-H and MSS tumors (P < 0.0001) and between 
HNPCC and sporadic MSS tumors (P < 0.005) ‡ – The association of HLA class I loss with that of β2m and of APM 








Figure 3. Genetic analysis performed on tumors that have lost HLA class I expression. The different peaks correspond 
to different sizes from the PCR-amplified products. Peaks corresponding to the normal samples are represented in 
green whereas tumor samples are represented in blue. A, LOH analysis performed on the RST 41 sample with the 
polymorphic marker C141. The total loss of a normal allele (on top) illustrates the technical advantage of using flow 
cytometric sorting to identify LOH events. B, Frameshift mutations identified in different members of the APM 
machinery. On top a homozygous deletion in the sample RST 65 on the 4th exon of the Tapasin gene is shown. 
On the bottom, a heterozygous deletion in the sample RST 18 on the second exon of the TAP2 gene is shown. C, 
Frameshift mutation identified in one HNPCC case (h4) in the 2nd exon of the B2M gene. Because flow sorting was 
not performed in the HNPCC cases, we cannot determine whether the frameshifts are homo- or heterozygous due 
to contamination with normal DNA. 
(hereditary and sporadic forms) where LOH 
seems to be limited.
Frameshift mutation screening of the 
microsatellite sequences present in the 
coding regions of the HLA class I, APM 
components and B2M genes was performed 
on all cases with aberrant HLA class I 
expression (Figures 3B,C). However specific 
genes were only analyzed when lack of 
expression of the encoded proteins was 
detected by immunohistochemistry. Of the 
classical HLA class I genes only HLA-A and 
-B were analyzed since HLA-C does not carry 
any microsatellite repeat in its coding region. 
Ten RST cases and 20 HNPCC control cases 
with normal expression of β2m and APM 
components were screened for frameshift 
mutations and none was detected.
Frameshift mutations were mainly found 
in the MSI-H cases (both sporadic and 
hereditary forms). At least one mutation in 
an APM component gene was found in 6 of 7 
sporadic MSI-H tumors that lost expression 
of one or more APM components. The 
cases), and Calnexin and ERp57 (1 case). 
Loss of the LPM10 protein was detected in 
neither sporadic RST nor HNPCC tumors. 
The HNPCC cases h38 and h49 lost the 
expression of TAP2 and LMP7 respectively.
LOH and frameshift analysis
Polymorphic markers around the classical 
HLA genes (A, B and C), TAP 1 and TAP2 
genes were used to study LOH and reveal 
possible chromosomal aberrations that 
could relate to loss of HLA class I expression 
(Figure 3A). In HNPCC cases, LOH analysis 
was only performed around the HLA genes 
since loss of the TAP1 and TAP2 proteins 
was rarely associated with HLA class I loss. 
LOH was more frequent in the MSS tumors 
(50%) than in the MSI-H sporadic (20%) 
and HNPCC (6%) tumors with loss of HLA 
class I expression (P < 0.05) (Figures 4, 5). 
Furthermore, the patterns of LOH in the 
MSS cases might indicate loss of the entire 
6p21.3 region, in contrast to the MSI-H cases 
39


































































































































































































































































































































































































































































































































































































































































































































































































































































































































single sporadic MSI-H case that lost β2m 
expression also presented with a single 
frameshift mutation in the B2M gene. Of 
the 13 sporadic MSI-H cases in which loss 
of HLA class I expression was associated 
neither with APM component nor with β2m 
loss as detected by immunohistochemical 
staining, one presented with a frameshift 
in an HLA gene (case 39, Figure 4, Table 
2) while 3 other cases showed LOH of the 
markers adjacent the HLA genes (cases 7, 
44 and 67). One frameshift mutation was 
found in the Tapasin gene in a MSS case (case 
62). From 15 HNPCC tumors that lost β2m 
expression at least one mutation was found in 
8 cases (Figure 5). Three of the latter showed 
2 mutations localized in different stretches. 
In the remaining 17 HNPCC cases that solely 
lost HLA class I expression, only 4 showed 
genetic abnormalities. LOH was found in 
the HLA region in cases h16, h56 and h120 
(data not shown). A frameshift mutation in 
one of the HLA genes (HLA - B) was found 
in one case (h99, Figure 5). In neither of the 2 
HNPCC cases that immunohistochemically 
lost the expression of one of the APM 
components an APM frameshift mutation 
was found.
DISCUSSION
Abnormalities in HLA class I cell surface 
expression are commonly observed in 
tumors and are interpreted as a mechanism 
ins – insertion; del – deletion; hom – homozygous; het – heterozygous; the numbers before and after del/ins indicate 
the location of the microsatellite repeat containing the frameshift mutation and the number of affected nucleotides 
respectively. 
LOH Criteria for HNPCC
1 2 3 1 2 1 2 3
h4 0 0 del del 0 hMLH1  mutant
h8 0 0 0 0 0 hMLH1  mutant
h26 0 0 0 0 0 MSI-H, no methylation on hMLH1 , IHC MSH6 neg
h38 0 0 del 0 0 hMLH1  mutant
h45 0 0 0 0 0 MSI-H, no methylation on hMLH1
h49 0 0 0 0 0 MSH2  mutant
h54 0 0 del 0 ins hMLH1  mutant
h87 0 0 del 0 0 hMSH6  mutant
h93 0 0 0 0 0 hMSH6  mutant
h97 0 0 0 0 0 hMLH1  mutant
h99 0 0 0 0 0 hMLH1  mutant
h103 0 0 0 0 ins MSI-H, no methylation on hMLH1 , IHC MSH6 neg
h118 0 0 0 0 ins PMS2  mutant
h119 0 0 0 0 del hMLH1  mutant





















Figure 5. LOH and frameshift analysis was performed on HNPCC tumors that simultaneously lost HLA class I and 
β2m expression. LOH markers: (see legend from Figure 4 for key). Frameshift markers:HLA A: 1 – 4th exon 7(C) 
2 – 5th exon 3 (GGA); HLA – B: 3(GA) & 3(CA); B2M: 1 – 1st exon 4(CT), 2 – 2nd exon 4(GA). & 5(A), 3 – 2nd 
exon 5(A) (key: ins – insertion; del – deletion; 0 – no mutation; IHC -immunohistochemistry). 
Table 2. Frameshift mutations description in RST.
RST Mutation description
18 TAP2 (341–346)del1 – het
39 HLA-A (621–627)ins1 – het
65 B2M (341–345)del1 – hom; Tapasin (1217–1222)del1 – hom; Calreticulin (418–422)ins1 – hom
69 TAP1 (362–366)del1 – hom
78 ERp57 (675–680)del2 – hom; ERp57 (1459–1464)del1 – hom
90 HLA-A (621–627)ins1 – het; Calnexin (1476–1483)del1 – het
94 Tapasin (1217–1222)del1 – het
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by which tumor cells evade the host immune 
system (1). In colorectal cancer, especially 
in MSI-H tumors, the high degree of 
lymphocytic infiltrate in some cases may 
suggest an active immune response during 
tumor development (24,25). Moreover, 
MSI-H tumors might cause increased 
immune reactivity as a consequence of the 
high amounts of aberrant frameshift peptides 
they generate (8,18). A selective pressure by 
CTLs upon these tumors would favor the 
outgrowth of tumor cells that lost HLA class 
I expression at the cell surface allowing them 
to surpass the action of the immune system.
Applying immunohistochemistry on tissue 
arrays, we compared HLA class I expression 
in both sporadic RST (MSI-H and MSS sub-
groups) and HNPCC tumors. RST were 
chosen because of the high percentage of 
MSI-H cases in this specific tumor type 
(43). Indeed, immunohistochemical staining 
with monoclonal antibodies showed that 
HLA class I loss was frequent in the MSI-H 
cases analyzed when compared to their 
MSS counterpart. This finding supports 
the hypothesis that MSI-H tumors face 
greater selective pressure to lose HLA class 
I expression, as described by Kloor et al. (8). 
However, we have shown for the first time 
that distinct molecular mechanisms underlie 
HLA class I loss in sporadic MSI-H and 
HNPCC colon cancers. In the latter, HLA 
class I loss was preferentially associated with 
that of β2m, while in the former HLA class I 
loss was associated with that of one or more 
APM components (P < 0.0001).
We investigated the genetic abnormalities 
underlying the HLA class I loss of expression. 
They included LOH on chromosome region 
6p21.3 (encompassing HLA class I and TAP 
genes), mutations in APM components and 
mutations in B2M.
Loss of heterozygosity at 6p21.3 was most 
prevalent in MSS tumors. This is consistent 
with the observation that these tumors 
frequently possess gross chromosomal 
aberrations and are often aneuploid (13). 
Moreover, since LOH events in MSS 
tumors normally comprise large areas of a 
chromosome, LOH on 6p21 might not be 
a direct consequence of selective pressure 
directed to the loss of HLA expression but 
instead to other genes within the same 
chromosomal region. The general absence of 
LOH in MSI-H tumors suggests that this is 
not the major mechanism by which the cells 
abrogate HLA class I expression.
The genome’s coding regions contain 
multiple microsatellite repeats, which 
are considered hotspots for mutations in 
mismatch repair-deficient tumors (26). Such 
repeats are also present within the exons of 
the APM components, B2M, HLA-A and 
HLA-B genes. In about half of the MSI-H 
cases, loss of expression of HLA class I was 
concordant with the detection of one or 
more mutations in these genes. We have 
discovered novel mutations in the antigen 
presenting machinery genes; Tapasin, Erp57, 
Calreticulin and Calnexin in colorectal 
cancer. Previous reports associated the loss 
of HLA class I expression in MSI-H tumors 
with defects on β2m molecule (7,9). However, 
the authors did not distinguish the sporadic/
hereditary nature of the tumors that were 
studied. We cannot exclude that the MSI-H 
cases included in these studies were mainly 
HNPCC tumors.
The reason sporadic MSI-H tumors would 
target APM members for inactivation and 
HNPCC would target the β2m chaperon 
is unclear. One possibility worth further 
exploration is that the various mutations 
suggest different immune-escape 
mechanisms for thwarting distinct anti-
tumor responses. HNPCC tumors can have 
an age of onset before the 5th decade of 
life while sporadic MSI-H tumors appear 
generally around the 7th decade of life (26); 
one would therefore predict that the alertness 
and robustness of the immune system would 
be higher in HNPCC patients leading to 
a stronger, or at least different selective 








been recently suggested that the JC polyoma 
virus plays a role in the oncogenicity of 
colon tumors with an identical phenotype 
to sporadic MSI-H tumors (27). Although 
speculative, the presence of the JC virus 
might be implicated in a different immune 
response between sporadic MSI-H and 
HNPCC tumors.
The advantages of different escape 
mechanisms (loss of APM members vs. 
abrogation of β2m) are not understood. The 
only known function of APM members is 
facilitating the expression of HLA classical 
molecules in complex with endogenous 
peptides. Thus, one would expect that only 
these HLA molecules would be affected by 
failure of the antigen processing machinery. 
On the other hand, it is accepted that 
cell surface expression of non-classical 
HLA molecules (e.g. HLA -G, -E) also 
depends on β2m, so the function of these 
highly specialized molecules would be 
compromised if β2m were mutated or lost. 
These molecules might play an important 
role in regulation of immune cell activity 
by inhibiting or activating its function. 
Therefore, MSI-H sporadic tumors that have 
lost expression of both HLA and an APM 
component and HNPCC tumors with lost 
β2m expression might behave differently or 
present a different kind of interaction with 
cells from the immune system. For instance, 
Yamamoto et al. have described a correlation 
between B2M mutations and unfavorable 
prognosis in colorectal cancer (28).
We separately analyzed the presence of 
the characteristic BRAF V600E somatic 
mutations in the RST cohort (data not 
shown). Forty-percent of MSI-H sporadic 
tumors presented with this mutation which 
was absent in the MSS tumors. It was 
previously described that this mutation is 
also absent in HNPCC tumors (29). V600E 
was distributed equally between tumors that 
lost vs. retained expression of HLA class I in 
the sporadic MSI-H cases.
CONCLUSION
HLA class I aberrations are found at 
varying frequencies in different colorectal 
tumor types and are caused by distinct 
genetic mechanisms. Chiefly, sporadic and 
hereditary MSI-H tumors follow different 
routes toward HLA class I loss of expression 
supporting the idea that these tumors 
follow different evolutionary pathways in 
tumorigenesis. The resulting variation in 
immune escape mechanisms may have 
repercussions in tumor progression and 
behavior.
METHODS
Patient material and tissue microarrays
Two tissue microarrays were constructed from 
formalin-fixed, paraffin-embedded tissues as described 
previously (30). One array, previously described 
(31), included colorectal tumor specimens from 129 
suspected HNPCC patients with MSI-H colon tumors 
of which 75 cases were analyzed in the present study 
after confirmation of their HNPCC status: 73.3% (n 
= 55) of the latter possessed a germline pathogenic 
mutation in MLH1 (n = 24), MSH2 (n = 18), MSH6 
(n = 12) or PMS2 (n = 1), the remaining were MSI-H, 
without methylation of the MLH1 promoter and/
or with immunohistochemical loss of the MSH2/
MSH6 heterodimer and/or possessed a very young age 
at diagnosis of colon cancer (<50 yrs old). All cases 
possessed a positive family history for MSI-H tumors. 
The second tissue array included 3 tumor tissue cores 
from 81 sporadic right-sided colon cancer cases resected 
between 1990 and 2005 at the Leiden University 
Medical Center (Leiden, The Netherlands) and at the 
Rijnland Hospital (Leiderdorp, The Netherlands). The 
81 patients in the latter array consisted of 47 females 
and 34 males with a mean age of 71.15 years (SD= 
9.958). Approximately 60% (n = 48) of these cases were 
classified as MSS while the remaining (n = 33) possessed 
a MSI-H phenotype. The microsatellite instability 
status of the tumors was determined according to 
recommendations of the National Cancer Institute/ICG-
HNPCC (15). Moreover all MSI-H sporadic cases have 
lost the expression of the MLH1/PMS2 heterodimer as 
assessed by immunohistochemistry. The sporadic status 
of the MSI-H right-sided tumors (RST) was confirmed 
by methylation analysis of the MLH1 promoter using 
a methylation-specific MLPA assay as previously 
described (32). All MSI-H sporadic cases presented with 
hypermethylation at the MLH1 promoter.
The present study falls under approval by the Medical 
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Ethical Committee of the LUMC (protocol P01–019). 
Cases were analyzed following the medical ethnical 
guidelines described in the Code Proper Secondary Use 
of Human Tissue established by the Dutch Federation of 
Medical Sciences (33).
Immunohistochemistry
Standard three-step, indirect immunohistochemistry 
was performed on 4-μm tissue sections transferred to 
glass slides using a tape-transfer system (Instrumedics, 
Hackensack, NJ), including citrate antigen retrieval, 
blockage of endogenous peroxidase and endogenous 
avidin-binding activity, and di-aminobenzidine 
development.
The following primary antibodies were used: the 
mAb HCA2 which recognizes β2m-free HLA-A (except 
-A24), -B7301 and -G heavy chains (34,35) ; the mAb 
HC10, which recognizes a determinant expressed on all 
β2m-free HLA-B and C heavy chains and on β2m-free 
HLA-A10, -A28, -A29, -A30, -A31, -A32 and -A33 heavy 
chains (supernatant kindly provided by Dr. J. Neefjes, 
NKI, Amsterdam, The Netherlands and Dr. H. L. Ploegh, 
MIT, Boston, MA) (34,36); TAP1 specific mAb NOB1; 
LMP2-specific mAb SY-1; LMP7-specific mAb HB2; 
LPM10-specific mAb TO-7; Calnexin-specific mAb TO-
5; Calreticulin-specific mAb TO-11; Tapasin-specific 
mAb TO-3; ERp57-specific mAb TO-2 (37-39); TAP2-
specific mAb (BD Biosciences Pharmingen, San Diego, 
CA); rabbit anti-β2m polyclonal Ab (A 072; DAKO 
Cytomation, Glostrup, Denmark); anti-MLH1 (clone 
G168–728; BD Biosciences) and anti-PMS2 (clone 
A16-4; BD Biosciences). Secondary reagents used were 
biotinylated rabbit anti-mouse IgG antibodies (DAKO 
Cytomation), goat anti-rabbit IgG antibodies (DAKO 
Cytomation), and biotinylated-peroxidase streptavidin 
complex (SABC; DAKO Cytomation).
Loss of expression was defined by complete lack of 
staining in membrane and cytoplasm (HCA2, HC10, and 
anti-β2m), in the nucleus (anti-MLH1 and anti-PMS2), 
in the peri-nucleus/endoplasmic reticulum (NOB1, anti-
TAP2, TO-2, TO-3, TO-5, TO-7, and TO-11), or in the 
cytoplasm (SY-1, HB2, and TO-7), but with concurrent 
staining in normal epithelium, stroma or infiltrating 
leukocytes. HLA class I expression was considered to 
be lost when one of the HLA class I antigen-specific 
antibodies gave a negative result alongside a positive 
internal control (lymphocytic infiltrate).
Flow cytometric sorting
The flow cytometric sorting procedure, including 
tissue preparation, staining and flow cytometry analysis 
was performed as described previously (40). Briefly, 2 
mm diameter punches from selected areas of formalin-
fixed paraffin embedded colorectal carcinomas were 
digested enzymatically in a mixture of 0.1% collagenase 
I-A (Sigma-Aldrich, St Louis, MO, USA) and 0.1% 
dispase (Gibco BRL, Paisley, UK). After determination 
of cell concentration, one million cells were incubated 
with 100 μl of mAb mixture directed against keratin 
and vimentin containing clones MNF116 (anti-keratin; 
IgG1; DAKOCytomation, Golstrup, Denmark), AE1/
AE3 (anti-keratin; IgG1; Chemicon International 
Inc, Temecula, CA, USA), and V9-2b (anti-vimentin; 
IgG2b; Department of Pathology, LUMC (41)). Next 
day, cells were incubated with 100 μl of premixed FITC 
and RPE-labelled goat F(ab’)2 anti-mouse subclass-
specific secondary reagents (Southern Biotechnology 
Associates, Birmingham, AL, USA). After washing, cells 
were incubated with 10 μM propidium iodide (PI) and 
0.1% DNase-free RNase (Sigma). The next day cells were 
analyzed by flow cytometry. A standard FACSCalibur 
(BD Biosciences) was used for the simultaneous 
measurement of FITC, RPE, and PI. Tumor and normal 
cell populations were flow-sorted using a FACSVantage 
flow-sorter (BD Biosciences) using the FACSCalibur 
filter settings. Sorting was only performed on samples 
included in the RST array due to shortage of material 
from the HNPCC cases. DNA from flow-sorted tumor 
material was isolated as described by Jordanova et al. 
(42). DNA from non-sorted material was isolated using 
Chelex extraction as described previously (43).
LOH and fragment analysis
Markers for loss of heterozygosity (LOH) analysis 
were chosen from the dbMHC database (44) to map the 
chromosome 6p21.3 region between HLA-A and TAP2. 
They were MOGc, D6S510, C125, C141, D6S2444, TAP1 
and M2426. A “linker” sequence of 5’-GTTTCTT was 
added to the 5’ terminus of all reverse primers (45). 
LOH was defined as allelic imbalance >2 in the HNPCC 
cases (non-sorted) and allelic imbalance >5 in the sorted 
RST (46).
To detect frame-shift mutations in the HLA-A, 
HLA-B, B2M, LMP2, LMP7, LMP10, TAP1, TAP2, 
Calnexin, Calreticulin, ERp57 and Tapasin genes, 28 
pairs of primers (Table 3) were constructed surrounding 
non-polymorphic microsatellite regions within the 
coding regions.
Statistics
Significance values were calculated using the software 
package SPSS 10.0.7 (SPSS Inc., Chicago, IL, USA).
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Human leukocyte antigen (HLA) class 
I expression defects frequently occur in 
colorectal cancers bearing mismatch repair 
(MMR) deficiencies and are interpreted 
as immune evasion mechanisms to avoid 
cancer cell recognition and elimination 
by the immune system. MMR-deficient 
tumours are thought to be more prone 
to lose HLA class I expression, due to 
their frequent generation of aberrant 
peptides which can stimulate a cytotoxic 
T-cell-mediated response. MUTYH-
associated polyposis (MAP) is a colorectal 
cancer syndrome caused by defects in the 
MUTYH DNA repair enzyme. Impairment 
of MUTYH activity could lead to a surplus 
of mutated peptides which would be 
presented to cytotoxic T-cells through the 
HLA class I molecules. 
We have studied the frequency of 
HLA class I expression defects in MAP 
carcinomas and have compared it to those 
observed in MMR-deficient and -proficient 
colorectal tumours. Immunohistochemical 
detection of the expression of HLA class 
I, β2-microglobulin (β2m), and antigen-
processing machinery molecules was 
performed in 37 primary MAP carcinomas 
and nine metastases resected from 29 MAP 
patients. Furthermore, we sequenced the 
B2M, TAP1, and TAP2 genes. 
Defects in HLA class I expression 
were detected in 65% of primary MAP 
carcinomas, affecting 72% of patients. HLA 
class I expression abnormalities were often 
concomitant with β2m expression loss and 
mutations in the B2M gene. Loss of HLA 
class I expression is thus a frequent event 
in MAP carcinomas, similarly to MMR-
deficient colorectal tumours. 
The extensive mutagenic background 
of these tumours most likely triggers a 
strong selective pressure, exerted by the 
immune system on the tumour, which 
favours the outgrowth of tumour cell 
clones with an immune evasive phenotype. 
Our data provide additional evidence for 
a link between DNA repair deficiencies 
and altered HLA class I phenotypes in 
colorectal cancer.
INTRODUCTION
During cancer development, tumour 
cells may elicit cytotoxic T-lymphocyte-
mediated immune responses—partly a 
consequence of accumulated gene mutations 
that are translated into altered peptides (1, 
2). Tumour cell expression of the human 
leukocyte antigen (HLA) class I-antigen 
complexes is essential for T-cell recognition 
of aberrant peptides and subsequent 
activation (3). Consequently, alteration of 
HLA class I cell surface expression provides 
an effective mechanism by which tumours 
can escape detection by immune cells (4, 5). 
Multiple mechanisms have been shown to 
underlie defects in HLA class I expression 
by tumour cells; they include mutations in 
the individual HLA class I genes, HLA-A, 
-B, and -C, located on chromosome 6p21.3 
(6); loss of heterozygosity (LOH) at 6p21.3 
(7); mutations in β2-microglobulin (β2m) 
(8, 9), the molecule required for the cell 
surface expression of HLA class I antigens; 
and defects in components of the HLA class 
I-associated antigen-processing machinery 
(10–12). The antigen-processing machinery 
consists of the proteasome components 
delta, MB1, and Z; the immunoproteasome 
components LMP2, LMP7, and LMP10; the 
peptide transporters TAP1 and TAP2; and 
the chaperones calnexin, calreticulin, ERp57, 
and tapasin. The immunoproteasome mostly, 
although not exclusively, generates peptides 
from endogenous proteins. TAP1 and TAP2 
facilitate peptide translocation from the 
cytosol into the lumen of the endoplasmic 
reticulum, where the peptides are loaded 
onto the HLA class I molecules with the aid 
of several chaperones (13).
We and others have previously described 
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a higher frequency of HLA class I defects 
in colorectal cancers presenting with DNA 
mismatch-repair (MMR) deficiency, in 
comparison with MMR-proficient tumours 
(12, 14, 15). Furthermore, we found that 
distinct molecular events underlie HLA 
class I loss, depending on the aetiology 
of the tumours; Lynch syndrome-related 
cancers presented with mutations in the 
β2m molecule, while sporadic microsatellite-
unstable tumours mainly showed alterations 
in the antigen-processing machinery 
components (12).
Microsatellite instability is a form of 
genetic instability that occurs in about 15% 
of colorectal cancers. Microsatellite-unstable 
sporadic tumours have a phenotype resulting 
from the epigenetic inactivation of the MMR 
gene MLH1 (16). Microsatellite instability is 
also the hallmark of Lynch syndrome-related 
tumours, in which germline mutations of the 
MMR genes MLH1, MSH2, MSH6, and PMS2 
can be found (17). Their inactivation destroys 
a cell’s ability to repair base–base mismatches 
and small insertions or deletions in repetitive 
stretches, leading to an accumulation of 
frameshift mutations that become translated 
into abnormal peptide sequences (18). These 
tumours are therefore thought to be more 
able to stimulate a cytotoxic T-cell-mediated 
immune response, due to their frequent 
generation of aberrant peptides (19, 20). 
Consequently, these tumours are probably 
subjected to a selective pressure that favours 
the outgrowth of tumour cells with the ability 
to escape from recognition and destruction 
by the host immune system.
Another colorectal cancer syndrome in 
which DNA repair deficiencies are implicated 
is MUTYH-associated polyposis (MAP) 
(21). MAP is a recessive inheritable disease 
caused by bi-allelic MUTYH inactivating 
germline mutations (22). Carriers may 
develop 10–500 polyps until the fifth decade 
of their lives and most of these patients will 
present with a colorectal cancer (23, 24). The 
MUTYH protein is a base excision repair 
enzyme involved in the repair of one of the 
most frequent and stable forms of nucleotide 
oxidative damage: 8-oxo-7,8-dihydro-2’-
deoxyguanosine (8-oxodG). This structure 
readily mispairs with adenosine residues, 
leading to G : C > T : A transversions after 
DNA replication (25). MUTYH acts by 
scanning the daughter DNA strand for any 
mispaired adenines, either with guanines 
or 8-oxodGs, and subsequently excising 
them (26). Defects in this repair mechanism 
incapacitate the cell’s ability to reverse 
such mispairs, leading to an accumulation 
of mutations. The APC and KRAS genes 
are frequently mutated in MAP tumours, 
although not exclusively presenting the 
typical transversions (21, 27, 28).
We hypothesized that, similarly to MMR-
deficient tumours, MAP tumours could be 
more prone to stimulate a cytotoxic T-cell-
mediated immune response, due to their 
frequent generation of aberrant peptides. 
Hence, these tumours could also be subjected 
to a strong selective pressure favouring the 
outgrowth of cancer cells that acquire an 
immune evasive phenotype.
We aimed to study the occurrence of 
HLA class I expression deficiencies in MAP 
carcinomas, as well as the expression of HLA 
class I chaperones and antigen-processing 
machinery components. Furthermore, we 
investigated the occurrence of mutations 
in β2m or antigen-processing machinery 
components when their expression was lost.
RESULTS
HLA class I, β2m, and antigen-processing 
machinery components’ expression
Defects in HLA class I expression were 
detected in 24/37 primary carcinomas and in 
all nine tumour metastases (seven of which 
derived from patient 29), comprising 72% 
of the patients included in the study (Table 
1). The HCA2 and HC10 antibodies detect 








respectively. Within the group of tumours 
with HLA class I defects, six primary 
carcinomas (25%) presented with total 
loss of HLA class I (concomitant loss of 
HCA2 and HC10); another two carcinomas 
(8%) presented with loss of solely the 
HLA-A molecule (as assessed with HCA2 
antibody); and the remaining carcinomas 
(67%) presented heterogeneous patterns 
with alternating positive and negative 
tumour areas for HLA class I expression 
(Figure 1). All seven metastases from patient 
29 expressed HLA class I, although no 
membranous expression was detectable with 
the HCA2 antibody (Figure 1).
We also investigated the concurrent loss of 
expression of β2m and antigen-processing 
machinery components with that of HLA 
class I. Loss of β2m expression was detected 
in 58% of carcinomas with HLA class I 
expression abnormalities (Table 1); four of 
these presented with total loss of HLA class 
I (Figure 2B), two exclusively lost HLA-A 
expression, and eight cases possessed a 
heterogeneous pattern of HLA class I 
expression (Figures 2C and 2D) normally 
accompanied by a similar pattern of β2m 
expression. This heterogeneous pattern was 
frequently recognized within one tissue 
core, as represented in Figures 2C and 2D. 
Notably, the seven tumour metastases from 
patient 29, presenting with a peri-nuclear 
pattern of expression for HLA class I, showed 
total absence of β2m expression, further 
confirming the existence of HLA class I 
expression abnormalities (Figures 2E and 
2F).
Concurrent loss of antigen-processing 
Table 1. Expression of HLA class I, β2m, and antigen-processing machinery components in MAP carcinomas.
− altered expression in tumour cells,* Seven of the nine metastases belonged to one patient.
machinery components and HLA class I 
expression was observed in five cases: four 
primary tumours (17% of tumours with 
HLA class I expression abnormalities) and 
one tumour metastasis (Table 1). TAP1 
and/or TAP2 were lost in all of these cases, 
while tapasin was found to be abrogated in 
patient 26 (Figure 1). Except for the latter, all 
other tumour tissues failed to present a clear 
internal positive control, thus not allowing 
the confirmation of loss of expression of 
those molecules. Loss of expression of the 
antigen-presenting machinery components 
and β2m was mutually exclusive.
Fourteen adenomas, from ten patients, 
were analysed for HLA class I and β2m 
expression. Only three (21%) displayed 
aberrant HLA class I expression which 
was always heterogeneous throughout the 
adenomatous tissue. All three belonged 
to patients with HLA class I deficiencies 
in at least one of their carcinomas. Loss of 
expression of β2m was found in one of the 
adenomas with HLA class I deficiencies.
B2M, TAP1, and TAP2 sequencing
We sequenced the coding regions of the 
B2M, in all tumours for which DNA was 
available, and TAP1 and TAP2 genes in the 
tumours that lacked expression of these 
molecules. All mutations are listed in Figure 
1. Mutations in B2M were identified in eight 
primary carcinomas. In one case (patient 1, 
tumour 1), the mutation was not related to loss 
of either β2m or HLA class I expression. Two 
other tumours conserved β2m expression 
MAP carcinomas HLA class I expression β2m loss APM loss
Primary tumors + 13 (35.1%) 0 0
n = 37 − 24 (64.9%) 14 (58.3%) 4 (16.7%)
Metastases + 0 0 0
n = 9* − 9 8 1
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Figure 1. Expression of HLA class I was detected with HCA2 (HLA-A) and HC10 (HLA-B, HLA-C) antibodies. 
Additionally, the expression of the chaperone β2-microglobulin and the antigen-processing machinery components 
were determined. + = positive; 0+ = loss of expression with internal positive control; 00 = loss of expression without 
internal positive control; 0+ het = heterogeneous expression, with positive and negative tumour cells; +* = non-
membranous (cytoplasmic HLA class I expression); 0+ het* = heterogeneous expression, with positive (cytoplasmic 
HLA class I expression) and negative tumour cells. B2M mutations were investigated in all cases where DNA was 
available, and TAP1 and TAP2 mutations were screened when one of these molecules was not expressed. − = No 
mutations found with the complete gene sequence available.
but presented deficiencies in HLA class I 
expression (patient 2 and patient 22, tumour 
1). The remaining all had detectable defective 
β2m expression. Eight metastases with HLA 
class I loss of expression carried a mutation 
in the B2M gene. All seven belonging to 
patient 29 presented with the same mutation 
in the starting codon of the B2M gene (c.1A 
> T). Starting-codon, splice-site or frameshift 
mutations were associated with loss of β2m 
expression. The carcinoma from patient 2 
displayed a truncating mutation in the 3’ end 
of the gene which did not lead to abrogation 
of β2m expression. Amino-acid substitutions 
were associated with retained β2m expression 
and in one case, a heterogeneous pattern 
of expression (patient 22, tumour 2). The 
complete B2M sequence was available for six 
additional tumours without HLA classI/β2m 
aberrations and no mutations were found. 
Only one mutation was found in the peptide 








STOP codon in the third exon of the TAP2 
gene. The usage of formalin-fixed material 
for DNA extraction did not always allow 
full gene sequencing for all cases, implying 
a possible underestimation of the number of 
samples carrying mutations.
DISCUSSION
HLA class I expression defects have 
been frequently reported in several cancers 
(5, 6, 10, 11, 29). These are interpreted as 
mechanisms adopted by tumours to escape 
immune surveillance and thereby avoid 
tumour cell recognition and destruction. 
We, and others, have previously described a 
predisposition for MMR-deficient colorectal 
tumours to lose HLA class I expression 
(12, 14, 15). MMR-deficient tumours are 
thought to be more competent at triggering 
an immune response, due to their increased 
mutagenic potential, when compared with 
MMR-proficient tumours, which translates 
into an accumulation of frameshift peptides 
that might work as tumour neo-antigens 
(8, 19, 20). The immune reaction might 
function as a selective pressure that favours 
the outgrowth of tumour cell clones that 
have lost HLA class I expression. In the 
present work, we investigated the occurrence 
of HLA class I expression deficiencies in 
MAP carcinomas. Patients with MAP carry 
biallelic mutations in the MUTYH gene, 
which prevents the cells from accumulating 
point mutations derived from DNA oxidative 
damage. Like Lynch syndrome and sporadic 
MSI-H tumours, one would expect that MAP 
carcinomas would be competent at triggering 
immune responses and would be similarly 
subjected to a selective pressure, imposed by 
the immune system, favouring the outgrowth 
of cells with absent HLA class I expression.
We identified HLA class I expression 
abnormalities in the majority of MAP 
carcinomas analysed, both in the primary 
carcinomas and in the tumour metastases. 
In total, 72% of patients carried carcinomas 
(68% of primary tumours) that exhibited 
HLA class I expression deficiencies. 
Previously, we described that approximately 
half of MSI-H sporadic tumours and Lynch 
syndrome-related tumours had defects in 
HLA expression, while colon mismatch-
repair-proficient tumours presented HLA 
class I expression abnormalities in only a 
minority of the carcinomas analysed (17%) 
(12). Put together, these observations 
provide additional evidence of the prevalence 
of HLA class I expression alterations in 
tumours carrying defects in DNA-repairing 
molecules. Furthermore, we analysed 14 
adenomas from the same cohort of patients 
for HLA class I and β2m expression but 
these were seldom, as was previously 
reported for colorectal adenomas (30). The 
increased mutagenic load and cytotoxic 
T-cell infiltration of carcinomas probably 
constitute an environment with greater 
selective pressure for immune evasive events 
than at adenoma stages.
Intriguingly, the majority of defects found 
in MAP carcinomas were in the form of 
heterogeneous patterns of HLA class I 
expression within the tumours, suggesting 
that MAP carcinomas are composed of 
different clones with respect to HLA class 
I expression. Such a phenotype was not 
observed in MSI-H tumours (data not 
shown). We previously reported that MAP 
carcinomas frequently display multiclonality 
for DNA content (31, 32), further supporting 
our observations. One piece of circumstantial 
evidence for increased immunogenicity 
of MMR-deficient tumours is the dense 
infiltration of the epithelial compartments 
of MSI-H carcinomas by T-cells, a hallmark 
of the histopathology of MMR-deficient 
tumours (33, 34). We also observed a higher 
incidence of moderate/marked infiltration by 
T-cells in the epithelium of MAP carcinomas, 
when compared with microsatellite-stable 
tumours (data not shown).
In the work of Dierssen et al., we dissected 
the most common mechanisms by which 
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Figure 2. (A) Immunohistochemical detection of HLA class I expression with HCA2 antibody in the carcinoma 
from patient 11, displaying membranous expression in tumour cells. (B) HLA class I-negative carcinoma (large ar-
row) with positive internal control (small arrow) (patient 28). (C, D) Heterogeneous pattern of HLA class I expres-
sion; focal loss of HLA class I expression (large arrow) presented together with positive membranous expression 
(small arrow) (C, patient 17, tumour 2; D, patient 22, tumour 1). (E) Cytoplasmic accumulation of HLA class I in a 
case with β2m loss of expression, depicted in F (patient 29, metastases 4).
HLA class I expression was altered in 
sporadic MSI-H and hereditary (Lynch 
syndrome) MMR-deficient tumours (12). 
We found that B2M mutations occurred 
preferentially in Lynch syndrome tumours, 
while sporadic MSI-H tumours presented 
more frequently with deficiencies at the 








components. Kloor et al. also reported that 
mutations in the B2M gene occurred more 
frequently in Lynch syndrome-derived 
tumours than in sporadic MSI-H tumours 
(9). We investigated whether the loss of any 
of these molecules was coupled to HLA class 
I expression deficiencies in MAP carcinomas; 
expression of β2m was absent in 58% of 
MAP primary carcinomas with altered HLA 
class I expression, while at least one of the 
antigen-processing machinery components 
was not detected in 18% of MAP carcinomas 
with HLA class I alterations. Although 
speculative, it is interesting to underline 
that carcinomas derived from both MAP 
and Lynch syndromes preferentially lose 
β2m expression coupled to HLA class I 
deficiencies. A functional explanation for 
these observations remains elusive, but 
perhaps distinct reactions (both qualitative 
and quantitative) by the immune system, 
depending on the age of onset of the tumours, 
could condition the type of mechanisms that 
lead to HLA class I expression deficiencies.
Middeldorp et al. reported extensive 
chromosomal recombination events in MAP 
carcinomas (31). These frequently translate 
into LOH with maintenance of chromosome 
copy number (copy neutral LOH) throughout 
the genome. LOH at chromosome 6p21 
(HLA locus) and 15q22–23 (B2M locus) was 
frequently detected, but no association with 
HLA class I or β2m expression was found 
(data not shown). In cases with maintenance 
of HLA class I expression, LOH at 6p might 
conceal an alternative HLA class I phenotype, 
not identified by immunohistochemistry: loss 
of one parental haplotype and amplification 
of the other. Each HLA class I haplotype has 
distinct affinities to different antigens, based 
on their peptide sequence. Therefore, the 
loss of one haplotype excuses the tumour 
cell from presenting a specific pool of 
peptides to the immune system. Moreover, 
the maintenance of one parental haplotype 
allows recognition of the ‘self ’ by the immune 
cells and might impede the destruction of 
tumour cells by natural killer (NK) cells 
(4). No polymorphisms in β2m have been 
associated with different efficiencies in 
peptide presentation; it is therefore difficult 
to determine whether LOH in 15q, in cases 
without HLA class I abnormalities, has any 
effect on HLA class I/antigen presentation.
The high frequency of alterations in HLA 
class I expression in MMR-deficient and 
in MAP carcinomas constitutes a strong 
handicap for the employment of T-cell-
based immunotherapy on advanced tumours 
(35). On the other hand, the fact that the 
immune system is able to recognize tumour 
antigens during cancer development reveals 
an opportunity for the development of 
vaccination strategies based on frequently 
altered peptides across different MAP 
carcinomas (36, 37). Additionally, memory 
T-cell responses could be used in the 
diagnostic setting, if they occurred at an 
early stage of tumour development, thus 
adding possibilities for the development of 
less invasive screening techniques, especially 
in carriers of hereditary syndromes.
We are the first to report HLA class 
I abnormalities in MAP carcinomas. It 
provides additional evidence that tumours 
carrying defects in DNA base repair 
mechanisms are more prone to undergo 
immune escape mechanisms. With this 
work, all known syndromes and subsets of 
sporadic colorectal tumours arising in the 
context of DNA repair deficiencies have now 
been linked with higher frequencies of HLA 
class I abnormalities, when compared with 
DNA base repair-proficient tumours.
METHODS
Patient material
Patients were recruited throughout The Netherlands. 
Germline DNA mutation analysis of the whole MUTYH 
gene was performed on lymphocytic DNA or DNA 
from formalin-fixed, paraffin-embedded normal tissue 
as described previously (38, 39). Informed consent was 
obtained according to protocols approved by the LUMC 
ethics review board (02–2004). A tissue microarray was 
constructed as reported previously (40) and contained 
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Table 2. Primer sequences utilized to sequence the B2M, TAP1 and TAP2 genes.
18mer M13 derived sequences were added to the 5’ end the primer (Fw – TGTAAAACGACGGCCAGT, Rv – CAG-
GAAACAGCTATGACC)
Primer Forward Reverse
B2M ex1 GGCTGGGCACGCGTTTAA GGAGAGGAAGGACCAGAG
B2M ex2.1 TACCCTGGCAATATTAATGTGT GATAGAAGACCAGTCCTT
B2M ex2.2 CTTACTGAAGAATGGAGAGAG GATAGAAAGACCACTCCTTGC
B2M ex3 ATTCTGCCAGCTTATTTCTAACC GGGTTATCATGTTAGAGCTGTC
TAP1 ex1.1 CGATTTCGCTTTCCCCTAA AGCTAGCCATTGGCACTCG
TAP1 ex1.2 GCCAGTAGGGGAGGACTCG GCACCAGCAGGGAGAATATG
TAP1 ex1.3 ACTGCTACTTCTCGCCGACT CGCAGCTAATGGCTTCAAA
TAP1 ex1.4 CAACGGTTGGCTCCAAGA GACTTCCCCAGTGCAGTAGC
TAP1 ex1.5 GACTTGCCTTGTTCCGAGAG GACGCACAGGGTTTCCAG
TAP1 ex1.6 CGCCTTCGTTGTCAGTTATG TTTGATTCCTGTCCCAGTCC
TAP1 ex2 TGTGCGTGACCTCTCTTCTC ACCCTTCCAACTCCCTCATTTGC
TAP1 ex3 CACACCCTGATCCCCTTTTT GGGGAGATCAAAGCAGATGT
TAP1 ex4.1 GGCATCCTGGCTCATTGTTA GACACTGATCCCCAGAGCAT
TAP1 ex4.2 ACGTCCACCCTGAGTGATTC TCTGGGAGATGAGGGTCTGT
TAP1 ex5.1 CCGTGTGACATCTCTTGTCC ATAGGCCACAGCCTCCTTCT
TAP1 ex5.2 GGAATCTCTGGCAAAGTCCA ACGGCATCTTAAGGACAAGG
TAP1 ex6 TTGTGTCCCCTCCAGATTTC ATCACACTGGGGAGTGAAGG
TAP1 ex7.1 GCTGGCAAGCAGACTACCTC GACAAGGCCCTCCAAGTGTA
TAP1 ex7.2 CTGTGGGCTCCTCAGAGAAA GCCAGTGGAATACAGGGAGT
TAP1 ex8 GCCTTGGTAGCCTCTTATCG CAAGCCACCTGCTTCCATAC
TAP1 ex9 CCCATGTGCCTTGTTCTATG GGGTGGTGAGATGAGTGGAG
TAP1 ex10 GTTCTCATCTTGGCCCTTTG TTGGGTGGGATATAGCCATT
TAP1 ex11.1 CTCTGACGGTCCGATGTCTT CCCTTTTTCTCCATGAGCTG
TAP1 ex11.2 CAGGCTGACCACATCCTCTT GAAAAGGGAGGGAGATGGAG
TAP2 ex2.1 CACCCCCATGATTTCTCATC AATCCCAGCAGCCCTCTTAG
TAP2 ex2.2 GCTGTGGGGGCTGCTAAA TCAGAACAGCCCACAGTGAC
TAP2 ex2.3 GGGGCTCAGCTGGTCACT CCTCCAACTCACAACGTCCT
TAP2 ex3 GGGCACCAGCACATTCTT AGATTTGGGGCTAGCAAATG
TAP2 ex4 GCTTGCTCCTCTGTTTCACC TGGGAATCTCAGACCTGGAC
TAP2 ex5 CCTCACCTGCTCTGTCCTTC CCCTTACATGCACGCTCAC
TAP2 ex6.1 AGCATCTCACTGGCTGGAGT GCGACAGACTTCATGCTCCT
TAP2 ex6.2 CAGACCGTTCGCAGTTTTG GGCTCCTTTCACAACCACTC
TAP2 ex7 GAAGATTCCCAGCCTCATCTC CCCAGGAGTCCACAAAGAAA
TAP2 ex8 TCTCCCATTCCTGTTTTCCA GGTTTCCTCCCTCTTTCAGG
TAP2 ex9 GGCAGGCCCTTAACTCTTTT CTGTCTTCTCCCTCCTCACC
TAP2 ex10 ATAGTCCTCTGCCCCTGTCC TTTACTGAAGGAGCAAGCTTACAA
TAP2 ex11 GCACTTGTCCCTCCTTGTGT CCTGCCCTCTCACGGTACT
TAP2 ex12 TGGTGTCCATCTCATTCCTG CGGGAATAGAGGTCCTGTCC
carcinoma tissue from 37 primary carcinomas and 
nine metastases (one lymph node and eight distant 
metastases), derived from 29 MAP patients, represented 
by more than four (mean = 4.5, SD = 1.7) 0.6-mm-
diameter tissue cores. Such a number of tissue cores 








heterogeneity and thus produce reliable results (41). The 
tissue array also included 14 adenomas resected from 
the above patients. The cohort’s age mean was 51.2 years 
old (SD = 9.9). The majority of primary carcinomas 
were localized in the right-sided colon (73%) and the 
remaining had a sigmoid/rectum localization. Tumours 
were staged according to Dukes’ classification: one 
was Dukes’ A, 22 B, six C, and six D (three patients; 
one patient presented with four primary tumours and 
one distant metastasis). Patient samples were handled 
according to the medical ethical guidelines described 
in the Code Proper Secondary Use of Medical Sciences 
(http://www.federa.org).
Immunohistochemistry
Standard three-step, indirect immunohistochemistry 
was performed on 4 µm tissue sections transferred to 
glass slides using a tape-transfer system (Instrumedics, 
Hackensack, NJ, USA), including citrate antigen 
retrieval (citrate buffer, pH 6.0), blockage of endogenous 
peroxidase and endogenous avidin-binding activity, and 
diaminobenzidine development.
The following primary antibodies were used: the 
monoclonal antibody (MAb) HCA2, which recognizes 
β2m-free HLA-A (except -A24), -B7301, and -G heavy 
chains (42, 43); the MAb HC10, which recognizes a 
determinant expressed on all β2m-free HLA-B and 
-C heavy chains and on β2m-free HLA-A10, -A28, 
-A29, -A30, -A31, -A32, and -A33 heavy chains 33, 35; 
TAP1-specific MAb NOB1; LMP2-specific MAb SY-1; 
LMP7-specific MAb HB2; LPM10-specific MAb TO-
7; calnexin-specific MAb TO-5; calreticulin-specific 
MAb TO-11; tapasin-specific MAb TO-3; ERp57-
specific MAb TO-2 (45–47); TAP2-specific MAb (BD 
Biosciences Pharmingen, San Diego, CA, USA); rabbit 
anti-β2m polyclonal Ab (A 072; DAKO Cytomation, 
Glostrup, Denmark); and anti-granzyme B (clone 
11F1; Novocastra Laboratories, Newcastle upon Tyne, 
UK). Secondary reagents used were biotinylated rabbit 
anti-mouse IgG antibodies (DAKO Cytomation), goat 
anti-rabbit IgG antibodies (DAKO Cytomation), and 
biotinylated-peroxidase streptavidin complex (SABC; 
DAKO Cytomation).
All antigen-processing machinery components’ 
antibodies, except TAP2 MAb, were kindly provided 
by Dr Soldano Ferrone (Roswell Park Cancer Institute, 
Buffalo, NY, USA).
Loss of expression was defined as a complete lack 
of staining in the membrane and cytoplasm (HCA2, 
HC10, and anti-β2m), in the peri-nucleus/endoplasmic 
reticulum (NOB1, anti-TAP2, TO-2, TO-3, TO-5, TO-7, 
and TO-11), or in the cytoplasm (SY-1, HB2, and TO-
7), but with concurrent staining in normal epithelium, 
stroma or infiltrating leukocytes.
B2M, TAP1, and TAP2 sequencing
The B2M, TAP1, and TAP2 genes were screened for 
mutations in their coding regions. DNA was isolated 
from three 0.6-mm-diameter tissue cores retrieved from 
a tissue block after evaluation of the corresponding 
haematoxylin and eosin-stained tissue slide. After 
dewaxing, the tissue cores were incubated overnight at 
56 °C in 0.3 ng/µl proteinase K and purified the next day 
with the Genomic Wizard kit (Promega, Leiden, The 
Netherlands). PCR was performed in a 25 µl volume 
containing 20 µM of primer pair and 12 ng of sample 
DNA. 18mer M13-derived oligos were added to the 
5’ end of each primer in order to facilitate sequence 
analysis. Primer sequences are presented in Table 2. 
Amplified products were sequenced at The Leiden 
Genome Technology Center (Leiden, The Netherlands).
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Lynch syndrome colorectal cancers often 
lose human leukocyte antigen (HLA) class 
I expression. The outgrowth of clones with 
immune evasive phenotypes is thought 
to be positively selected by the action of 
cytotoxic T cells that target HLA class I–
positive cancer cells. To investigate this 
hypothesis, we related the type and density 
of tumor lymphocytic infiltrate in Lynch 
colorectal cancers with their HLA class I 
phenotype and clinicopathologic stage.
HLA class I expression was assessed 
by means of immunohistochemistry. 
Characterization of tumor-infiltrating 
lymphocytes was carried out by using a 
triple immunofluorescence procedure 
that allowed the simultaneous detection 
of CD3-, CD8-, and granzyme B (GZMB)-
positive cells. Additional markers were 
also used for further characterization 
of an elusive CD3−/CD8−/GZMB+ cell 
population.
We discovered that high tumor 
infiltration by activated CD8+ T cells 
correlated with aberrant HLA class I 
expression and associated with early tumor 
stages (P < 0.05). CD8+ T cells were most 
abundant in HLA class I heterogeneous 
tumors (P = 0.02) and frequent in HLA class 
I–negative cases (P = 0.04) when compared 
with HLA class I–positive carcinomas. An 
elusive immune cell population (CD45+/
CD8−/CD56−/GZMB+) was characteristic 
for HLA class I–negative tumors lacking 
lymph node metastases (P < 0.01).
The immune system assumes an 
important role in counteracting the 
progression of Lynch colorectal cancers 
and in selecting abnormal HLA class I 
phenotypes. Our findings support the 
development of clinical strategies that 
explore the natural antitumor immune 
responses occurring in Lynch syndrome 
carriers.
TRANSLATIONAL RELEVANCE
Lynch syndrome–associated colorectal 
cancers are known to evoke a strong reaction 
from the immune system of patients. We 
discovered that early staged tumors were 
more densely infiltrated by activated CD8+ 
T cells than tumors diagnosed at advanced 
stages. Moreover, we observed an immune 
cell population that was specifically 
associated with nonmetastasized Lynch 
syndrome colorectal cancers. Those cells 
lacked most common lymphocytic surface 
antigens. Altogether, our findings support 
that the immune system plays a major role in 
counteracting colorectal cancer progression 
in patients with Lynch syndrome. We 
propose the development of novel clinical 
strategies, inspired by the natural antitumor 
immune response occurring in patients with 
Lynch syndrome. Considering that Lynch 
colorectal cancers rapidly acquire immune 
evasive phenotypes, special relevance should 
be given to prophylactic approaches.
INTRODUCTION
Expression of human leukocyte antigen 
(HLA) class I/antigen complexes, in human 
cells, is essential for a competent immune 
surveillance (1). CD8+ T cells are capable 
of recognizing and eliminating target cells 
that present non–self-antigens in an HLA 
class I context (2). Accordingly, HLA class I 
loss is interpreted as a mechanism, adopted 
by tumors, to escape immune surveillance 
and thereby avoid tumor cell recognition 
and destruction (3). We, and others, 
previously reported that the majority of 
DNA mismatch- and base excision repair–
deficient colorectal cancers lose HLA class 
I expression (4–7). Those include sporadic 
mismatch repair–deficient as well as Lynch 
syndrome colorectal cancers and MUTYH-
associated polyposis (MAP) colorectal 
cancers, respectively. The frequency of HLA 
class I deficiencies in these tumors was 
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found to be considerably higher than the 
one observed for DNA repair–proficient 
colorectal cancers (5, 7). Both mismatch- 
and base excision repair–deficient colorectal 
cancers are thought to be particularly prone 
to evoke antitumor immune responses due 
to their pronounced mutator phenotypes (8). 
Such immune reaction will act as a vector of 
selective pressure that favors the outgrowth 
of tumor clones that acquired immune 
evasive phenotypes.
Multiple mechanisms have been shown to 
underlie defects in HLA class I expression by 
tumor cells; they include mutations in the 
individual HLA class I genes, HLA-A, -B, and 
-C, located on chromosome 6p21.3 (9); loss 
of heterozygosity at 6p21.3 (10); mutations 
in β2-microglobulin (B2M; ref. 11), the 
molecular chaperone required for the cell 
surface expression of HLA class I antigens; 
and defects in components of the HLA class 
I–associated antigen-processing machinery 
(12, 13). For unknown reasons, β2m defects 
were preferentially associated with HLA class 
I loss in hereditary colorectal cancers (Lynch 
syndrome and MAP), whereas sporadic 
mismatch repair–deficient tumors were 
frequently affected by antigen-processing 
machinery defects (5, 14).
The loss of HLA class I expression, in 
mismatch- and base excision repair–deficient 
colorectal cancers, constitutes a strong 
handicap for the employment of T-cell–
based immunotherapeutic approaches 
(15, 16). On the other hand, evidence 
for T-cell–mediated antitumor immune 
responses could support the development of 
prophylactic vaccination strategies based on 
peptides that are frequently mutated in the 
aforementioned colorectal cancers (17, 18). 
This approach is of particular importance 
for individuals carrying an increased risk for 
developing colorectal cancer at an early age. 
Lynch syndrome is an autosomal, dominant 
disease caused by the germline inactivation 
of one copy of either MLH1, MSH2, MSH6, 
or PMS2 mismatch repair genes (19). Patients 
with Lynch syndrome have an increased 
lifetime risk of developing colorectal cancer, 
as well as other cancer types, when compared 
with the general population (20). Currently, 
endoscopic surveillance constitutes the most 
effective approach to increase life expectancy 
of affected individuals (21).
The development of T-cell–based 
prophylactic vaccination strategies for 
patients with Lynch syndrome requires 
additional evidence that T cells are the drivers 
of immune selection in Lynch colorectal 
carcinomas. It has been previously reported 
that colorectal cancers carrying HLA class 
I defects are more densely infiltrated by T 
cells (22–24). However, these observations 
were not reproduced specifically in cohorts 
of mismatch repair–deficient tumors. 
Accordingly, those reports might carry a 
possible bias: Because both pronounced 
lymphocytic infiltration and HLA class 
I loss are hallmarks of mismatch repair–
deficient tumors it is difficult to establish 
a causal relation between the presence of 
lymphocytes and HLA class I abnormalities 
on consecutive series of colorectal cancers 
(8, 25, 26). Therefore, the current study 
was conducted on a homogeneous cohort 
of genetically proven Lynch colorectal 
carcinomas. We sought to characterize and 
quantify the lymphocytic infiltration present 
in Lynch colorectal carcinomas and relate it 
with their HLA class I expression status and 
clinicopathologic stage.
RESULTS
Lymphocytic infiltration of Lynch 
carcinomas associates with the HLA class 
I phenotype
Expression of HLA class I and β2m was 
assessed in 90 Lynch colorectal carcinomas. 
Altogether, 83% of tumors presented HLA 
class I defects (Table 1). Membranous HLA 
class I expression was completely lost in 58 








of HLA class I staining was observed 
in 17 carcinomas (Figure 1). The latter 
presented fields where tumor cells conserved 
membranous expression of HLA class I 
together with additional tumor areas where 
HLA class I expression was completely lost 
(Figures 1C and 1D). HLA class I alterations 
were accompanied by aberrant β2m 
expression in 51% of cases (Table 1). There 
was no difference in the distribution of HLA 
class I phenotypes between Lynch colorectal 
carcinomas with mutations in different 
mismatch repair genes (data not shown).
Qualitative and quantitative 
characterization of intraepithelial 
lymphocytic infiltration by means of triple 
immunofluorescence was possible for 83 
tumors. In a few cases (n = 7), the staining 
procedure was not successful due to poor 
fixation and/or age of the tissue. The 
combination of CD3, CD8, and GZMB 
markers allowed the discrimination between 
CD3+/CD8− cells (presumably CD4+ and 
γδ T cells), CD3+/CD8+ cells (CD8+ T 
Table 1. HLA class I phenotypes and density of lymphocytic infiltration in Lynch colorectal cancers.
a Medians differ significantly from the HLA class I–positive group. 
Figure 1. Three different HLA class I phenotypes were observed in Lynch colorectal carcinomas. Tumors were either 
HLA class I positive, with clear membranous expression of the HLA class I molecules (A); HLA class I negative, with 
total absence of HLA class I expression in tumors cells and respective positive internal control provided by stromal 
cells (B); and HLA class I heterogeneous, with HLA class I positive and negative tumor foci (C, D).
HLA class I status Tumors, n (%) % β2M loss Median Mean Median Mean Median Mean Median Mean
Positive 15 (17) — 6.13 20.78 39.10 62.86 16.85 31.96 1.03 3.30
Heterogeneous 17 (19) 26 8.73 19.56 72.88 111.9 51.74a 67.97 1.86 3.78
Negative 58 (64) 59 11.98a 23.51 60.58 90.39 35.33 54.38 4.96 a 23.03
CD3+/CD8−
CD8+ T cells 
(CD3+/CD8+)
Infiltrate density, n cells/mm2
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cells), and CD3+/CD8+/GZMB+ (activated 
CD8+ T cells; Figures 2A–D). No significant 
difference was detected between distinct 
HLA class I phenotypes for total CD8+ T-cell 
density (Figures 3A). However, HLA class 
I–negative and heterogeneous tumors were 
Figure 2. Density of lymphocyte infiltration in tumor fields (T) was determined by means of triple immunofluorescence. 
Antibodies against CD3 (red), CD8 (blue), and GZMB (green) were simultaneously used to identify CD3+/CD8− 
cells (presumably CD4+ or γδ T cells), total CD8+ T cells (CD3+/CD8+), and activated CD8+ T cells (CD3+/CD8+/
GZMB+; A–D). CD4+ or γδ T cells are represented in red, whereas CD3+/CD8+ cells (purple) correspond to CD8+ 
T cells. GZMB positivity in CD3+/CD8+ cells (green/white) reveals activated CD8+ T cells (A, arrowheads). Density 
of lymphocyte infiltration varied greatly among tumors (A and B). A large number of GZMB-positive cells, without 
colocalization of CD3 and CD8, were detected in some tumors (C and D, arrowheads). We attempted to characterize 
those cells by using a set of markers in combination with CD8 (blue) and GZMB (green). CD45 (red) was the 
only marker that clearly associated with the CD8−/GZMB+ cells (E, arrowheads). By means of bright-field double 








more densely infiltrated by activated CD8+ 
T cells than HLA class I–positive tumors (P 
= 0.02 and P = 0.04, respectively; Figure 3B). 
CD3+/CD8− cells (CD4+ and γδ T cells) 
were more frequent in HLA class I–negative 
tumors when compared with HLA class I–
positive (P = 0.01; Figure 3C). Among HLA 
class I–negative tumors, only the density of 
CD3+/CD8− cells (CD4+ and γδ T cells) was 
related to the β2m expression status. β2m-
negative cases were more densely infiltrated 
by these type of cells (P = 0.01; data not 
shown).
A population of cells with a CD3−/CD8−/
GZMB+ phenotype was detected in 82% of 
cases at various frequencies (Figures 2C and 
D). These cells were often localized in the 
stromal compartment, immediately adjacent 
to the tumor fields, but less frequently within 
the epithelium. CD3−/CD8−/GZMB+ 
cells were mostly restricted to HLA class I–
negative tumors (P = 0.004; Figure 3D).
The amount of CD8- and GZMB-positive 
cells relates to tumor stage of Lynch 
carcinomas
As the interaction between tumor and 
immune cells might have implications for 
tumor progression and dissemination, 
we compared the density of lymphocytic 
infiltration between different pathologic 
stages (TNM classification).
There was a clear correlation between the 
T staging of the primary tumor and the 
presence of CD8+ T cells, independently of 
their activation status (provided by GZMB 
staining). The total amount of CD8+ T 
Figure 3. Total CD8+ T cells were not distributed differently between tumors with different HLA class I phenotypes 
(A). Activated CD8+ T cells were more frequent both in HLA class I–negative (HLA−) and heterogeneous (HLA-h) 
tumors than HLA class I–positive cases (B). CD3+/CD8− (CD4+ and γδ T cells) were also more frequent in HLA 
class I–negative tumors (C). GZMB+ cells lacking CD3 or CD8 markers were characteristic for HLA class I–negative 
carcinomas (D). *, P < 0.05; **, P < 0.01. 
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cells was gradually smaller with increasing 
tumor stage (P < 0.05; ANOVA, Figure 4A). 
This difference was most striking when 
the analysis was restricted to HLA class I–
negative tumors (P = 0.002; Figure 4B). The 
same trend was observed for activated CD8+ 
T cells in all tumors (P = 0.04) and HLA 
class I–negative cases (P = 0.004; Figures 4C 
and D). No other lymphocyte population 
correlated with T staging.
Remarkably, abundance of the elusive 
CD3−/CD8−/GZMB+ cell population not 
only correlated with HLA-negative tumors 
but was also characteristic for lymph node–
Figure 4. The density of lymphocytic infiltration was related to tumor stage both for the primary tumor (T) and 
lymph node status (N). Total CD8+ T cells and activated CD8+ T cells were more frequent in earlier stages of the 
primary tumor (A–D). The elusive CD3−/CD8−/GZMB+ cell population was almost exclusively present in lymph 








negative carcinomas (P < 0.01; Figures 4E 
and F). All Lynch carcinomas with more 
than 10 CD3−/CD8−/GZMB+ cells per 
mm2 of tumor area did not present lymph 
node metastases. Furthermore, the only 2 
cases presenting metastases at distant organs 
also carried lower numbers of CD3−/CD8−/
GZMB+ cells (0 and 7 cells/mm2). None of 
the CD3+ lymphocyte populations related to 
the lymph node status of tumors.
Characterization of the CD3−/CD8−/
GZMB+ cell population
The potential clinical significance of the 
CD3−/CD8−/GZMB+ cell population in the 
progression of Lynch carcinomas compelled 
us to further characterize these cells. Their 
clear association to HLA class I loss and 
lymph node–negative tumors supported 
the investigation of additional markers with 
a focus on natural killer (NK) cells. CD2, 
CD16, CD45, CD56, CD57, CD68, CD117, 
NKp46, and TCR-γ expression was assessed 
simultaneously with CD8 and GZMB 
markers (antibody description in Table 2).
The only marker that clearly associated 
with the CD3−/CD8−/GZMB+ cell 
population was CD45 (Figure 2E), thus 
confirming the hematopoietic nucleated 
lineage of these cells. CD56+ cells were rare 
and located nearby blood vessels (Figure 
5A). CD16 cells were abundant but did not 
colocalize with GZMB positivity (Figure 
5B). CD57+/CD8− cells were often found 
in the stromal compartment of tumors, and 
some displayed positivity for GZMB but 
CD57 failed to colocalize with the majority 
of CD8−/GZMB+ cells (Figure 5C). All 
other investigated markers did not colocalize 
with these cells, despite the presence of 
internal positive controls for the majority 
(data not shown). No NKp46+ cells were 
found in tumor tissues. We detected NKp46 
expression in tonsil tissues to rule out a 
failure of the staining procedure.
As GZMB expression could be derived 
from granulocytes, we conducted a bright-
field, double staining of CD8 and GZMB 
together with hematoxylin counterstaining 
to discern the nuclear morphology of CD8−/
GZMB+ cells. The nuclei from CD8−/
GZMB+ cells were nonlobated and easily 
discriminated from polymorphonuclear 
granulocytes (Figures 2F and 5D).
This CD45+/CD8−/CD56−/GZMB+ 
cell population presented consistently 
throughout the staining procedures a 
higher amount of GZMB+ granules when 
compared with activated CD8+ T cells. 
Morphologically, these cells also appeared to 
be considerably larger than T lymphocytes 
(Figures 2F and 5D).
DISCUSSION
We characterized the quality and density 
of lymphocytic infiltrate, in a cohort of 
Lynch colorectal cancers, in the context of 
the HLA class I expression status of tumors 
Table 2. Description of primary antibodies utilized for the characterization of tumor infiltrating lymphocytes.
Antigen Antibody Host/Isotype Dilution Company Antigen expression Secondary antibody
CD3 ab828 Rabbit polyclonal 1:200 Abcam T cells goat anti-rabbit IgG-Alexa Fluor 546
CD8 4B11 Mouse IgG2b 1:200 Leyca Mycrosystems CD8+ T cells goat anti-mouse IgG2b-Alexa Fluor 647
CD8 c8/144B Mouse IgG1 1:400 DAKO CD8+ T cells goat anti-mouse IgG1-Alexa Fluor 546
Granzyme B GrB-7 Mouse IgG2a 1:400 DAKO Cytotoxic T cells; NK cells goat anti-mouse Ig2a-Alexa Fluor 488
CD2 AB75 Mouse IgG1 1:10 DAKO T and NK cells goat anti-mouse IgG1-Alexa Fluor 546
CD16 DJ130c Mouse IgG1 1:200 Ab Serotech NK cells, neutrophils, monocytes, macrophages goat anti-mouse IgG1-Alexa Fluor 546
CD45 2B11+PD7 Mouse IgG1 1:100 DAKO Hematopoietic nucleated cells except plasma cells goat anti-mouse IgG1-Alexa Fluor 546
CD56 123C3 Mouse IgG1 1:100 DAKO NK cells, activated T cells goat anti-mouse IgG1-Alexa Fluor 546
CD57 HNK-1 hybridoma Mouse IgM 1:20 ATCC NK cells, T cells goat anti-mouse IgM-Alexa Fluor 546
CD68 KP1 Mouse IgG1 1:200 DAKO Monocytes, macrophages goat anti-mouse IgG1-Alexa Fluor 546
CD117 A4502 Rabbit polyclonal 1:50 DAKO Mast cells, lymphoid progenitors goat anti-rabbit IgG-Alexa Fluor 546
NKp46 195314 Mouse IgG2b 1:100 R&D systems NK cells goat anti-mouse IgG2b-Alexa Fluor 647
TCR-γ γ3.20 Mouse IgG1 1:25 Thermo Fisher γδ T cells goat anti-mouse IgG1-Alexa Fluor 546
a
b
a All secondary antibodies were employed at a 1:200 dilution and purchased from Invitrogen; Rb - rabbit; Mo - 
Mouse; Go – goat. b The c8/144B anti-CD8 clone was only used in combination with the NKp46 marker due to 
isotype matching between latter that the anti-CD8 4B11 clone.
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and their clinicopathologic stage. We aimed 
to establish a relation between the makeup 
of the antitumor immune response and the 
HLA class I phenotype of tumors to support 
the notion of immune selection.
Both CD3+/CD8− cells (presumably CD4+ 
and γδ T cells) and activated CD8+ T cells 
were more frequent in HLA class I–negative 
tumors than HLA class I–positive cases. 
Moreover, tumors presenting heterogeneous 
patterns of HLA class I expression were 
infiltrated by remarkably high numbers 
of activated CD8+ T cells. It is tempting to 
speculate that these tumors were undergoing 
an active immune selection process, revealed 
by the presence of a heterogeneous HLA 
class I phenotype and the high affluence 
of activated CD8+ T cells. It is less evident 
why tumors that lost HLA class I expression 
Figure 5. The characterization of the CD3-/CD8-/GZMB+ cell population was made through the employment of 
various markers (red) together with CD8 (blue) and GZMB (green). CD8-/GZMB+ cells failed to co-localize with 
CD56 (A, arrows), CD16 (B) and CD57 (C). Few CD57+ cells displayed GZMB positivity (C, arrow). By means of 
bright-field double-staining we excluded that CD8-/GZMB+ cells were multi-nucleated granulocytes (D, arrow). 
remained infiltrated by activated CD8+ T 
cells as their effector function is dependent 
on the expression of HLA class I (27). 
Their persistent activation status might be 
supported by inflammatory signals derived 
from a past immune response against HLA 
class I–positive tumor cells. The elevated 
number of CD3+/CD8− cells (CD4+ and γδ T 
cells) in HLA class I–negative tumors alludes 
to the presence of T cells with helper and 
regulatory functions, capable of sustaining 
CD8+ T-cell activation (28, 29). On the 
other hand, the activation of CD8+ T cells 
might derive from the presence of antigen-
presenting cells which conserve the capability 
of presenting tumor antigens through an 
HLA class II route (30). Colorectal tumor 
cells were also shown to express HLA class 








and activation of CD8+ T cells (31). Michel 
and colleagues described that approximately 
one third of microsatellite instability-high 
(MSI-H) colorectal tumors presented 
membranous expression of HLA class II (32). 
We found a similar distribution for HLA-DR 
expression, the most abundantly expressed 
HLA class II molecule, in a subset of the 
current cohort. Its expression was associated 
with a higher density of infiltration by CD8+ 
T cells and CD3−/CD8−/GZMB+ cells (data 
not shown).
An elusive CD3−/CD8−/GZMB+ cell 
population was highly specific for HLA 
class I–negative tumors. Those cells were 
infrequent in tumors with heterogeneous 
expression of HLA class I and nearly absent 
in HLA class I–positive tumors. Strikingly, 
the presence of CD3−/CD8−/GZMB+ cells, 
in primary tumors, was highly predictive 
for the absence of lymph node metastases. 
Altogether, these observations compelled us 
to further characterize this population with 
focus on NK cell markers.
NK cells are CD3-negative cells possessing 
cytolytic activity, which can be triggered by 
the absence of HLA class I expression in 
target cells (33). They, thus, constitute an 
important component of the innate immune 
system, responsible for dealing with cells 
lacking important host markers–missing 
self hypothesis (34). Accordingly, NK cells 
have been regarded as promising vectors 
for the treatment of HLA class I–negative 
cancers (35). It is thought that tumor cells 
compensate for HLA class I loss by favoring 
the expression of additional NK-inactivating 
ligands and by losing antagonist ligands with 
NK-activating properties (36). Expression of 
HLA-G, an NK cell inhibitory ligand, was 
previously associated with a worse prognosis 
in colorectal cancer (37). We investigated its 
expression in a fraction of tumors composing 
the current cohort. HLA-G expression was 
never membranous and only detected in 16% 
of tumors (data not shown).
Several molecules have been proposed 
to be characteristic for NK cells or, at least, 
expressed by certain NK cell subsets (36). 
Our investigation included CD56, NKp46, 
and CD16, among others. All these markers 
were absent in the CD3−/CD8−/GZMB+ 
cell population, thus not supporting their 
classification as NK cells. Several other 
markers were investigated, which in turn 
excluded that these cells were mast cells 
or other granulocytes, macrophages, or 
γδ T cells. The only marker that clearly 
associated with the CD3−/CD8−/GZMB+ 
cell population was CD45, which confirmed 
their hematopoietic-nucleated lineage.
Considering that tumor staging is still 
the most important prognostic factor in 
colorectal cancer, the findings presented in 
this work might be of great relevance. We 
found a clear association between the type 
and density of immune cells, present in 
primary tumors, and their clinicopathologic 
stage. Furthermore, different immune 
cell populations related to the local 
invasive behavior of tumors or with their 
disseminating capacity. Our results support 
a role for CD8+ T cells in counteracting a 
local invasion of the mucosa by cancer cells 
but not in preventing the migration of tumor 
cells to adjacent lymph nodes. Conversely, 
the elusive CD45+/CD8−/CD56−/GZMB+ 
cell population was characteristic of tumors 
without lymph node metastases but did not 
relate to the extent of invasion of the primary 
tumor. Such a combination of immunologic 
responses might contribute to the improved 
survival of Lynch syndrome carriers when 
compared with patients with sporadic 
colorectal cancer (38, 39). The makeup 
and magnitude of the immune responses 
observed in patients were previously 
associated with the clinical prognosis and 
staging of colorectal cancer (40). Moreover, 
Galon and colleagues proposed that the type, 
density, and location of immune cells were 
better predictors of patient outcome than 
staging (41). However, the majority of studies 
did not discriminate between mismatch 
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repair–deficient and mismatch repair–
proficient colorectal cancers. Hence, the 
current study is the first to focus specifically 
on Lynch colorectal carcinomas.
While immune cells are important drivers 
of tumor selection, they could also hold 
the key for novel therapeutic or preventive 
interventions. The prophylactic vaccination 
of patients with Lynch syndrome with 
recurrent tumor antigens could elicit an early 
and robust CD8+ T-cell immune response 
(17, 18). Such a reaction could lead to tumor 
eradication or impede tumor progression 
from early stages. Of note, the presence of 
CD8+ T cells did not associate with the lymph 
node status of tumors, which highlights the 
role of the CD45+/CD8−/CD56−/GZMB+ 
cell population. The understanding of their 
role in counteracting tumor metastases could 
prove essential for the development of novel 




A cohort of 90 colorectal carcinomas, derived from 
86 patients with Lynch syndrome, was compiled. 
Corresponding formalin-fixed, paraffin-embedded 
tissues were collected throughout The Netherlands. 
All patients were carriers of genetically proven, 
pathogenic, germline mutations in MLH1 (n = 31), 
MSH2 (n = 25), MSH6 (n = 24), or PMS2 (n = 6) as 
determined by the Leiden Diagnostic Genome Centre 
of the Leiden University Medical Centre (LUMC), 
Leiden, The Netherlands. In addition, all except one 
patient, for whom extended clinical information was 
not available, fulfilled the revised Bethesda criteria 
for Lynch syndrome (42). Pathologic tumor- (lymph) 
node–metastasis (TNM) staging was retrieved from 79 
tumors of which 5 tumors were staged as T1, whereas 
19, 43, and 12 cases were staged as T2, T3, and T4, 
respectively. Twenty-four cases presented with lymph 
node metastases. Metastases in distant organs were 
only observed in 2 cases. The study was approved by 
the Medical Ethical Committee of the LUMC (protocol 
P01-019). Patient samples were handled according to 
the medical ethical guidelines described in the Code of 
Conduct for Proper Secondary Use of Human Tissue of 
the Dutch Federation of Biomedical Scientific Societies.
Immunohistochemistry
Expression of HLA class I and β2m were assessed 
by means of a 2-step indirect immunohistochemistry 
procedure on 4-μm tissue sections. Following 
deparaffinization and rehydration, the tissue sections 
underwent heat-mediated antigen retrieval in a 10 
mmol/L citrate buffer solution (pH 6). After cooling, 
endogenous peroxidase activity blockage was carried 
out with a 0.3% hydrogen peroxide/methanol solution. 
Thereafter, the sections were incubated overnight with 
one of the following primary antibodies: the monoclonal 
antibody (mAb) HCA2, which recognizes β2m-free 
HLA-A (except -A24), -B7301, and -G heavy chains (32, 
33); the mAb HC10, which recognizes a determinant 
expressed on all β2m-free HLA-B and -C heavy chains 
and on β2m-free HLA-A10, -A28, -A29, -A30, -A31, 
-A32, and -A33 heavy chains [refs. 33, 34; supernatants 
kindly provided by Prof. J. Neefjes, Netherlands Cancer 
Institute (NKI), Amsterdam, The Netherlands, and Prof. 
H.L. Ploegh, MIT, Boston, MA]; and the rabbit anti-
β2m polyclonal antibody A0072 (Dako). The following 
day, primary antibody binding was detected with 
the BrightVision Poly-HRP (horeradish peroxidase) 
Detection System (Immunologic). Scoring of HLA class 
I and β2m expression in tumor cells was always carried 
out against an internal positive control, provided by 
the staining of stromal cells. Negative controls were 
generated by replacing the primary antibodies by a 1% 
bovine serum albumin (BSA)/PBS solution during the 
procedure.
A double-staining immunohistochemistry procedure 
was carried out to study the morphology of CD3−/
CD8−/GZMB+ cells. Tissue sections were treated as 
described for the HLA class I and β2m staining, but 
heat-mediated antigen retrieval was done in a 1 mmol/L 
EDTA solution (pH 9) instead. Tissue sections were 
incubated overnight with a mixture of anti-CD8 [4B11, 
immunoglobulin G2b (IgG2b)], and anti-Granzyme B 
(GZMB; GrB-7, IgG2a) antibodies. Further detail on the 
primary antibodies is provided in Table 2. The following 
day, tissue sections were incubated with an anti-mouse 
IgG2a–HRP and goat anti-mouse IgG2b–AP solution 
(1:200; Southern Biotech). Staining development was 
carried out with 3,3’-diaminobenzidine (Dako) and 
Fast Red (Roche Applied Science) according to the 
manufacturer’s instructions.
Immunofluorescence
Characterization of lymphocytic infiltration 
in Lynch carcinomas was carried out with triple 
immunofluorescence. After deparaffinization and 
rehydration of the 4-μm tissue sections, heat-mediated 
antigen retrieval with a 1 mmol/L EDTA solution (pH 
9) and blockage of nonspecific antibody binding with 
10% normal goat serum (Dako) were carried out. A 
solution containing 3 primary antibodies was applied 








of fluorescently labeled secondary antibodies was used 
to detect primary antibody binding. A detailed list of 
primary and secondary antibodies used is provided 
in Table 2. Initial characterization of the lymphocytic 
infiltrate was done with a combination of anti-CD3, 
anti-CD8, and anti-GZMB antibodies. The CD3+/
CD8− cell population was considered to be composed of 
CD4+ and γδ T cells. The discovery of an elusive CD3−/
CD8−/GZMB+ cell population prompted us to screen 
additional tissue sections with primary antibodies 
directed against various hematopoietic markers. Anti-
CD2, -CD16, -CD45, -CD56, -CD57, -CD68, -CD117, 
-NKp46, and anti-TCR-γ antibodies were used in 
combination with anti-CD8 and anti-GZMB antibodies 
(antigens and dilutions provided in Supplementary Table 
S1). Immunofluorescence was detected with a LSM700 
confocal laser microscope (Carl Zeiss), equipped with 
a ZEISS LCI Plan-NEOFLUAR ×25/0, 8 DIC Imm 
Korr objective. Approximately 4 mm2 of tumor tissue 
was scanned. Density of lymphocytic infiltration was 
determined by dividing the number of intraepithelial (or 
immediately adjacent to the epithelium) lymphocytes 
by the tumor area. Both lymphocyte counting and 
measurement of the tumor area were conducted with 
the ZEN2009 LE software (Carl Zeiss). Negative controls 
were generated by replacing primary antibodies by a 1% 
BSA/PBS solution.
Statistical analyses
All statistical tests and graph construction were 
carried out with GraphPad PRISM (version 5.04). The 
Mann–Whitney U test was used when assessing the 
differences in the amount of lymphocytic infiltrate 
between HLA class I phenotypes and lymph node-
negative and -positive tumors. ANOVA was conducted 
for comparing lymphocyte density among the different 
T tumor stages (TNM classification).
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The TGF-β type 2 receptor gene 
(TGFBR2) is mutated in the majority 
of colorectal cancers that display a 
high degree of microsatellite instability 
(MSI-H). TGFBR2 contains a ten adenine 
((A)10) microsatellite that is a hotspot 
for the occurrence of nucleotide deletions 
and insertions in MSI-H cancers. As these 
translate to truncated protein forms it has 
generally been believed that the majority 
of MSI-H colorectal cancers lack TGFβR2-
mediated signaling. Nevertheless, previous 
works have shown that TGFβR2-deficient 
cell lines retain sensitivity to TGF-β. 
Here we demonstrate that TGF-β 
signaling is active in MSI-H colon tumors 
and that TGF-β activation in colorectal 
cancer cells occurs in a TGFβR2-dependent 
manner, despite the presence of truncating 
biallelic mutations in its gene. The ability 
of TGFBR2-mutated cells to respond to 
TGF-β was dependent on the preservation 
of TGFBR2’s microsatellite sequence. The 
replacement of the latter by synonymous, 
non-microsatellite sequences ablated 
the capacity of TGFBR2-mutated cells to 
respond to TGF-β. 
We postulate that the restoration of the 
reading-frame in TGFBR2-mutants occurs 
by transcriptional slippage. Notably, 
there is an apparent selective advantage 
for MSI-H colorectal cancers to retain 
responsiveness to TGF-β stimulation, 
which might support an important role for 
TGF-β signaling during carcinogenesis of 
these tumors. 
INTRODUCTION
The transforming growth factor-β (TGF-β) 
signaling pathway regulates cellular processes 
such as proliferation, differentiation and 
apoptosis. It constitutes an important 
mediator of tissue homeostasis, being crucial 
during tissue remodeling and inflammation 
(1-3). TGF-β signaling is found altered in 
a variety of tumors, including colorectal 
cancers (4, 5). It is believed that tumor 
cells acquire deleterious alterations in 
TGF-β signaling components in order to 
selectively escape its cytostatic effects (6, 7). 
Paradoxically, activation of TGF-β has also 
been associated with increased malignant 
behavior and metastatic capacity of cancer 
cells (8-10). 
TGF-β signaling initiates its cellular 
responses by binding a TGF-β type 2 
serine/threonine kinase transmembrane 
receptor, termed TGFβR2 (11). This 
interaction is facilitated by TGF-β type 3 
receptor (TGFβRIII), a co-receptor lacking 
kinase activity (12). Upon ligand binding, 
TGFβR2 attracts and phosphorylates an 
additional serine/threonine kinase receptor, 
TGFβR1, which in turn phosphorylates the 
transcription factors Smad2 and Smad3 
(13, 14). When activated, Smad2 and 
Smad3 associate with the co-Smad, Smad4, 
and this complex accumulates in the cell 
nucleus where it activates or represses 
expression of gene targets in conjunction 
with additional transcription factors (15). 
Although alternative, homologous receptors 
exist, TGFβR1 and TGFβR2 are considered 
fundamental for the transduction of TGF-β 
signaling responses in epithelial cells.
The manner by which colorectal cancers 
acquire alterations in the TGF-β pathway 
is related to the type of genetic instability 
observed in tumors. The majority of colorectal 
cancers display chromosomal instability 
(CIN), where gains or losses of entire 
chromosomal regions are frequent (16). Loss 
of genetic material affecting the chromosome 
region 18q21.1, where SMAD2 and SMAD4 
are located, is found in the majority of CIN 
colorectal cancers (17, 18). Mutations in any 
of these genes are almost exclusively found in 
SMAD4 (19), and when genetically inherited, 
explain a subset of cases of juvenile polyposis 
syndrome (20). Furthermore, Smad4 
expression is lost in approximately half of 
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CIN tumors and reduced in a significant 
proportion of cases (21, 22). The remaining 
fraction of colorectal cancers presents a 
microsatellite instability-high (MSI-H) 
phenotype, derived from a defective DNA 
mismatch repair (MMR) system (23). MSI-H 
colorectal cancers are characterized by the 
genome-wide accumulation of insertions 
and deletions at microsatellite sequences, 
peri-diploid DNA content and lack of 
gross chromosomal aberrations (24-26). 
Smad4 defects are uncommon in MSI-H 
colorectal tumors that instead target the 
TGF-β pathway at the receptor level (22). 
The third exon of the TGFBR2 gene contains 
a ten adenine microsatellite sequence that 
is found mutated in the majority of MSI-H 
colorectal cancers (26, 27). Deletions and 
insertions at this microsatellite produce 
frameshifts that lead to truncated forms of 
TGFβR2. Mutations are also frequent in 
ACVR2A, a gene that encodes an alternative 
type 2 TGF-β receptor and possesses two 
microsatellites of eight adenines at its third 
and tenth exons (28). Since the availability of 
either receptor is considered to be essential 
for TGF-β transduction, the current dogma 
of colorectal carcinogenesis assumes that this 
pathway is inactive in the majority of MSI-H 
cancers. Nevertheless, two independent 
reports have shown that cells carrying 
biallelic, truncating mutations in TGFBR2 
and ACVR2A remained sensitive to TGF-β 
stimulation in vitro (29, 30). Alterations in 
other components of the TGF-β pathway 
include: mutations in the 3’ untranslated 
region of the BMPR2 gene in the majority of 
MSI-H colorectal cancers (31), and mutations 
in the SMAD3 gene in approximately 4% of 
all colorectal cancers (32).
In this work, we sought to explain the basis 
of retained TGF-β sensitivity in TGFBR2-
mutated MSI-H colorectal cancer cells. We 
provide ex vivo and in vitro evidence that 
TGFβR2- and ACVR2A-deficient MSI-H 
colorectal cancer cells remain sensitive 
to TGF-β. Furthermore, we suggest that 
mutated TGFBR2 genes can still generate 
functional TGFβR2 proteins, most likely 
by reverting to their wild-type sequences 
by transcriptional slippage. Such form 
of “transcriptional instability” might be 
essential for the regulation TGF-β activity in 
a malignant context. 
RESULTS
The TGF-β pathway is active in MSI-H 
colon cancers
TGF-β signal transduction through 
TGFβR2 results in the phosphorylation 
of Smad2 at residues Ser465/467 (13). 
Thereafter, Smad2 associates with Smad4 and 
translocates to the nucleus where it activates 
or represses TGF-β transcription targets (14, 
15). Immunohistochemical detection of the 
phosphorylated form of Smad2 (P-Smad2) 
was used to assess whether TGF-β signaling 
was active in a cohort comprised of 76 
right-sided colon cancers (Figure 1). 
Approximately half of samples showed 
strong nuclear accumulation of P-Smad2 
while the remaining cases presented either 
weak (34%) or absent (16%) expression 
of P-Smad2 in the nucleus. A similar 
distribution was observed for MSI-H tumors 
specifically, suggesting that TGF-β signaling 
is active in right-sided colon cancers, 
independent of their background of genetic 
instability. P-Smad2 nuclear accumulation 
was positively correlated with nuclear Smad4 
expression (correlation coefficient = 0.266, 
P = 0.021, Spearman’s rank), with the latter 
being most frequently lost in microsatellite 
stable (MSS) tumors.
Smad2 phosphorylation in MSI-H colon 
cancers does not relate to TGFBR2 
mutation status
The TGFBR2 gene contains a ten adenine 
((A)10) microsatellite sequence in its third 








insertions in the majority of MSI-H colon 
cancers. We screened TGFBR2’s (A)10 
microsatellite for mutations in 32 MSI-H 
colon cancers by means of fragment analysis 
(Figure 2A). Prior to that, tumors were 
flow-sorted on the basis of cell’s keratin and 
vimentin expression in order to separate 
epithelial tumor cells from stromal cells. By 
removing stromal contaminants from the 
tumor samples we were able to determine 
the allelic state of TGFBR2 mutations 
(Figure 2A). Mutations in TGFBR2’s (A)10 
microsatellite were found in 94% of MSI-H 
colon cancers. One-nucleotide deletions 
were most frequent but two-nucleotide 
deletions and one nucleotide insertions 
were also observed (data not shown). Two-
thirds of mutated cases presented TGFBR2 
mutations in both alleles (Figure 2B). In a 
third of mutated cases, a wild-type allele 
could still be detected (Figure 2B). P-Smad2 
levels were not higher in tumor samples that 
conserved a wild-type TGFBR2 allele. 
In order to exclude that Smad2 
phosphorylation in MSI-H tumors could 
be due to activation of the TGF-β pathway Smad4P-Smad2
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Figure 1. P-Smad2 and Smad4 expression in colon cancers. P-Smad2 expression was detected either in the nucleus 
(A), suggesting an active TGF-β signaling, or at the cytoplasm (B). Nuclear localization of P-Smad2 was generally 
dependent on Smad4 expression (C). Downregulation of Smad4 expression was characteristic for microsatellite 
stable colon cancers.
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No mutation Biallelic mutation
Monoallelic mutation Polyclonal
through another type 2 receptor we 
investigated the presence of mutations in 
the ACVR2A gene. ACVR2A possesses two 
8 adenine ((A)8) microsatellite sequences in 
its third and tenth exons. Less than a third 
of MSI-H tumors still conserved a wild-type 
allele for ACVR2A (Figure 2B) and, similar 
to TGFBR2, no relation was found between 
the allelic state of ACVR2A mutations and 
P-Smad2 expression. In sum, the retention 
Figure 2. Mutations at TGFBR2 and ACVR2A 
microsatellite repeats. Analysis of TGFBR2 and ACVR2A 
microsatellites was performed by means of fragment 
analysis (A). Tumor alleles (green) were overlaid with 
their respective normal samples (blue). Four different 
allelic states were recognized after fragment analysis (B). 
Mutations in TGFBR2 and the tenth exon of ACVR2A 
most often affected both alleles.
of wild type alleles in type 2 TGF-β receptor 
genes does not explain TGF-β activation in 
MSI-H colon cancers.
TGFBR2-mutated colorectal cancer cell 
lines remain sensitive to TGF-β stimulation
Several MSI-H colorectal cancer cell lines, 
with distinct mutation backgrounds for 
TGFBR2 (Table 1), and one microsatellite 
stable cell line were tested for their ability 
to respond to TGF-β stimulation. This was 
achieved by transiently transfecting cells with 
a (CAGA)12-luciferase-reporter construct 
that contains binding sites for Smad3 and 
Smad4 and is effectively induced by cellular 
stimulation with TGF-β (33). Transcriptional 
reporter activity was greatly induced in 
LS180 and SW48 cells when stimulated with 
TGF-β, whereas it was only slightly induced 
in HCT116 and RKO cells (Figure 3A). 
LS411N cells remained insensitive to TGF-β 
stimulation (Figure 3A). The microsatellite 
stable cell line SW837, which is not known to 
carry mutations in components of the TGF-β 
pathway, demonstrated high sensitivity to 
TGF-β stimulation (Figure 3A). The two 
MSI-H cell lines in which TGF-β pathway 
stimulation was more pronounced (LS180 
and SW48), possess a biallelic one-base pair 
deletion in TGFBR2 (Table 1). Strikingly, 
TGF-β stimulation, perceived in the form 
of Smad2 phosphorylation at Ser465/467, 
could be suppressed selectively by targeting 
TGFBR2 transcripts by short-hairpin RNA’s 
in MSI-H colorectal cells, as demonstrated for 
the LS180 cell line (Figure 3B). Additionally, 
binding of a radio-labeled form of TGF-β to 
TGFβR2 could be detected in LS180 cells, 
although to a lesser extent than in RKO and 
SW837 cells, which possess at least one wild-
type TGFBR2 allele (Figure 4). 
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Figure 3. Induction of TGF-β pathway activity in a 
panel of colorectal cancer cell lines. TGF-β activation 
was possible in all colorectal cancer cell lines except 
LS411N (A), the only cell line carrying a biallelic two 
nucleotide deletion in TGFBR2 microsatellite (Table 
1). Means and standard deviations are depicted (* - P 
< 0.05, Bonferroni post test). Smad2 phosphorylation 
could be suppressed by employing shRNA’s directed 
against TGFBR2 transcripts, as demonstrated for LS180 
(B), a cell line carrying biallelic mutations in that gene.
Figure 4. Cross-linking of TGF-β ligand to TGF-β 
receptors in colorectal cancer cells. Following stimulation 
of cells with a radio-labeled TGF-β ligand, cross-linking 
was induced an immunoprecipitations carried out with 
anti-TGFβR1, TGFβR2 and TGFβR3 antibodies. A clear 
binding of the TGF-β ligand to TGFβR2 and TGFβR1 
(ALK5) could be observed for the microsatellite stable 
cell line SW837 and for RKO, a microsatellite unstable 
cell line with a monoallelic mutation in TGFBR2. Very 
weak binding to TGFBR2 could be detected in LS180 
cells. Immunoprecipitations with an anti-BMPR1A 
antibody were carried-out as negative controls.
TGF-β pathway activity in LS411 cells can 
be rescued by TGFBR2 constructs carrying 
deletions in (A)10 microsatellite
LS411N was the only colorectal cancer 
cell line that was unresponsive to TGF-β 
stimulation in the current study. Curiously, 
this cell line was also the only to carry 
a homozygous two-nucleotide deletion 
in TGFBR2’s (A)10 microsatellite (Table 
1). Of note, no MSI-H colon cancer was 
identified with biallelic two-nucleotide 
deletions in TGFBR2. We hypothesized that, 
depending on the type of mutation present 
in TGFBR2, TGF-β pathway activation was 
still possible without the presence of a wild 
type TGFBR2 gene. We produced wild-type 
and TGFBR2 mutant constructs with either 
one, two or three base-pair deletions in 
the (A)10 microsatellite (Figure 5A). Both 
(A)9 and (A)8 TGFBR2 constructs lead 
to the production of frame-shifted, early 
truncated TGFβR2 proteins, while the (A)7 
form originates an in-frame, one amino 
acid deletion. TGF-β pathway activity could 
be rescued by transfecting the (A)10 (wild-
type), (A)9 and (A)7 but not (A)8 constructs 
into LS411N cells (Figure 5A). Notably, 
transfection of LS411N cells with the (A)9 
TGFBR2 construct rescued TGF-β response 
to similar levels achieved by the construct 
representing the wild-type TGFBR2 form, as 
demonstrated by the (CAGA)12-luciferase-
reporter assay (Figure 5A).
We considered that the slippage of RNA 
polymerases at TGFBR2’s (A)9 mutated 
sequence could generate in-frame transcripts 
derived from one nucleotide insertions at 
the RNA level. We also speculated that the 
(A)8 microsatellite present in LS411N cells 
is more stable and less prone to generate in-
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pcDNA (A)10* (A)9* (A)8* (A)7*
TGFβR2 (A)10 (wt)*  atg aag gag aag aag aag cct ggt
                                  
TGFβR2 (A)9*           atg aag gag aag aag agc ctg gtg
                                   
TGFβR2 (A)8*           atg aag gag aag aag gcc tgg tga
                                   
TGFβR2 (A)7*           atg aag gag aag aag cct ggt gag







TGFβR2 (A)10 (wt)   atg aag gaa aaa aaa aag cct ggt
                                 
TGFβR2 (A)9            atg aag gaa aaa aaa agc ctg gtg
                                   
TGFβR2 (A)8            atg aag gaa aaa aaa gcc tgg tga
                                   
TGFβR2 (A)7            atg aag gaa aaa aag cct ggt gag
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Figure 5. Rescue of TGF-b sensitivity in LS411N colorectal cancer cells. Constructs containing different lengths of 
the TGFBR2’s microsatellite were produced in order to test their ability to rescue TGF-β activity in LS411N cells, 
which were shown to be insensitive to TGF-β stimulation (A). Transfection with the TGFBR2 constructs containing a 
microsatellite with 9 or 7 adenines rescued TGF-β sensitivity in these cells, while the TGFBR2 construct containing 8 
adenines failed to do so. Constructs containing synonymous substitutions at TGFBR2’s microsatellite were produced 
in order to remove the mononucleotide sequence pattern and consequently suppress genomic instability at this 
region (B). In contrast to what was previously observed, the (A)9 length construct carrying silent mutations at its 
microsatellite repeat failed to re-sensitize LS411N cells to TGF-β signaling. 
frame transcripts. In order to demonstrate 
that the retained TGF-β sensitivity in 
TGFBR2-mutated cells was indeed due 
to transcriptional slippage, we produced 
TGFBR2 constructs carrying synonymous 
mutations at the adenine stretches (Figure 
5B), thereby abrogating the microsatellite 
sequence. After transfecting LS411N cells with 
TGFBR2 constructs lacking a microsatellite 
sequence, TGF-β activation could not be 
rescued by the construct equivalent to 
the (A)9 microsatellite form (Figure 5B). 
These results support that TGFBR2 mutants 
presenting a (A)9 microsatellite sequence 
most likely revert to the wild-type sequence 
at the transcriptional level.
DISCUSSION
Genetic inactivation of TGFBR2 is a 
hallmark of MSI-H colorectal cancers (26, 
27). By becoming insensitive to TGF-β, 
tumors cells are thought to acquire a selective 
advantage by circumventing its growth 
inhibitory signals (6, 7). Furthermore, 
TGF-β is particularly important during 
inflammatory processes, being involved 
in the recruitment of lymphocytes and 
inflammatory cells to damaged tissues 
(2). MSI-H colorectal cancers are notable 
for presenting a marked intraepithelial 
infiltration by activated CD8 T cells but 
also elevated counts of inflammatory cells 
at the tumor sites (34-37). Accordingly, 








loss of HLA class I expression are frequent 
in MSI-H tumors (38-40). The abrogation 
of TGF-β signaling by MSI-H colorectal 
cancer cells could also constitute an immune 
escape mechanism in itself as leukocytes and 
macrophages produce this cytokine (41), 
(42). Conversely, while becoming insensitive 
to TGF-β, cancer cells may increase its 
production in order to modulate their 
microenvironment and cripple anti-tumor 
immune responses (43-45).
MSI-H colorectal cancers develop in the 
context of MMR deficiency that predisposes to 
the accumulation of nucleotide deletions and 
insertions at TGFBR2’s (A)10 microsatellite 
sequence. As expected, we found such 
alterations in the majority of MSI-H cancers 
analyzed and, most often, mutations affected 
both TGFBR2 alleles. Paradoxically, TGF-β 
signaling was found active in several MSI-H 
tumors, indicating that the presence of 
frameshift, truncating mutations in TGFBR2 
did not relate to the activation status of 
this pathway. We also excluded that the 
retained sensitivity to TGF-β could be due 
to signal transduction through ACVR2A, an 
alternative type 2 receptor for activins and 
BMPs, as we found biallelic mutations in 
ACVR2A in the majority of MSI-H cancers. 
Strikingly, we demonstrated, in vitro, that 
TGF-β activation in MSI-H colorectal cancer 
cells was dependent on TGFBR2 expression, 
despite the presence of biallelic inactivating 
mutations in this gene. Retained TGF-β 
sensitivity in MSI-H colorectal cancer 
cells that carried inactivating mutations 
in TGFBR2 was previously reported by 
two independent groups but the precise 
mechanisms of TGF-β activation were 
not clarified (29, 30). We propose that the 
restoration of the reading-frame of TGFBR2 
mutants occurs by transcriptional slippage, 
where nucleotide insertions or deletions at the 
RNA level allow the production of in-frame 
transcripts. To our knowledge, this is the first 
report describing such mechanism in cancer, 
while the restoration of reading frames or 
frameshifting due to transcriptional slippage 
has been reported for several organisms 
(46-49). A similar observation to the one 
presented in the current report was made for 
a mutant human apolipoprotein B (APOB) 
allele that causes hypobetalipoproteinemia 
(50). This allele possesses a deletion of a single 
cytosine that creates a novel microsatellite of 
eight adenines that is susceptible to produce 
in-frame transcripts containing nine 
adenines. Furthermore, as demonstrated 
here for TGFBR2, the replacement of the 
APOB’s-mutant microsatellite, abolished 
the capacity of this allele to generate 
productive transcripts (51). We considered 
the amplification of cDNA from TGFBR2 
mutants to prove the presence of wild-type 
transcripts but we could not exclude that the 
presence of wild-type transcripts was derived 
from PCR amplification artifacts.
TGF-β signaling has for long been 
considered to be ablated in the majority of 
MSI-H tumors due to the high frequency of 
inactivating mutations in TGFBR2. With this 
work we demonstrate that MSI-H colorectal 
cancer cells still depend on TGFβR2 to 
respond to exogenous TGF-β signals 
despite the presence of biallelic inactivating 
mutations in its gene. Interestingly, a 
selective advantage might be in place for 
cells that conserve some responsiveness 
to TGF-β. The most frequent TGFBR2 
mutations in MSI-H colorectal cancer cells 
are one base pair deletions that result in a 
microsatellite sequence of nine adenines. 
Such sequence remains prone to instability 
and if no selection would be imposed on 
this mutation, one would expect that further 
DNA replication errors would result in 
tumor clones carrying eight adenines. The 
latter sequence is considerably more stable 
and produces few artifacts in vitro but does 
not confer sensitivity to TGF-β signaling as 
demonstrated here. It is tempting to speculate 
that MSI-H colorectal cancers are driven 
to preserve some responsiveness to TGF-β 
signaling, although down-modulated, that 
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could perhaps avoid its tumor suppressive 




A tissue microarray (TMA) containing 76 formalin-
fixed, paraffin embedded right-sided colon cancer 
samples was utilized for the immunohistochemical 
detection of Smad4 and of the phosphorylated form 
of Smad2 (P-Smad2). Thirty-two cases were classified 
as MSI-H, according to the recommendations of the 
National Cancer Institute/ICG-HNPCC (52). Those 
MSI-H cancers were further processed for cell sorting 
of tumor and stromal cells by flow cytometry. The study 
was approved by the Medical Ethical Committee of 
the LUMC (protocol P01-019). Patient samples were 
handled according to the medical ethical guidelines 
described in the Code of Conduct for Proper Secondary 
Use of Human Tissue of the Dutch Federation of 
Biomedical Scientific Societies.
Cell lines: 
Six colorectal cancer cell lines were obtained from the 
American Type Culture Collection (ATCC, Manassas, 
VA, USA): five MSI-H (HCT-116, LS180, LS411, RKO 
and SW48) and one microsatellite stable cell line 
(SW837). Cells were cultured in RPMI1640 medium 
supplemented with 10% Foetal Bovine Serum and 100 
units/ml of Penicillin/Streptomycin (Gibco Invitrogen, 
Paisley, UK). 293T cells were used for the production of 
lentiviral particles.
Immunohistochemistry:
A standard two-step immunohistochemistry protocol 
was employed for the detection of P-Smad2 and Smad4 
in the colon cancer TMA. Four micrometer tissue 
sections were cut from the TMA and transferred onto 
glass slides using a tape-transfer system (Instrumedics 
Inc., Madison, IL, USA) and dried overnight at 37oC. 
Following deparaffinization and rehydration, tissue 
sections underwent heat-mediated antigen retrieval in 
10 mM citrate buffer solution (pH 6) for P-Smad2 or in 
10 mM Tris, 1 mM EDTA solution (pH 9) for Smad4 
staining. After cooling, endogenous peroxidase blockage 
was carried out with a 0.3% hydrogen peroxide/methanol 
solution. An additional blocking step with 10% normal 
goat serum (DAKO, Golstrup, Denmark) in phosphate 
buffered saline (PBS, pH 7.4) was performed. Thereafter, 
tissue sections were incubated over-night with the 
following primary antibodies: clone 138D4 (1:200, 
Cell Signaling Technology, Danvers MA, USA) which 
recognizes Smad2 only when phosphorylated at Ser 
465/467 and clone B-8 (1:400, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) directed against Smad4, 
diluted in 1% bovine serum albumin/PBS solution. 
The following day, after washing, tissue sections were 
incubated for thirty minutes with Powervision Poly-
HRP solution (Immunologic, Duiven, The Netherlands) 
and immunhistochemical staining was developed with 
DAB+ chromagen system (DAKO) for 5 minutes. 
Negative controls were generated by replacing the use 
of primary antibody with a 1% BSA/PBS solution. Three 
scoring categories were utilized: negative, weak, and 
strongly positive to which the numerical values of 0, 1 
and 2 were assigned for statistical analysis. Scorings were 
always performed in comparison to an internal positive 
control provided by stromal cells and/or leukocytic 
infiltrate.
FACS-sorting:
A flow cytometric sorting procedure was employed to 
allow the detection of TGFBR2 and ACVR2A mutations 
in separate fractions of tumor and stromal cells. Tissue 
preparation, staining and flow cytometry analysis 
was performed as described previously (53). Briefly, 
2 mm diameter tissue punches from selected areas of 
32 formalin-fixed, paraffin embedded MSI-H colon 
carcinomas were digested enzymatically in a mixture 
of 0.1% collagenase I-A (Sigma-Aldrich, St Louis, 
MO, USA) and 0.1% dispase (Gibco Invitrogen). After 
determination of cell concentration, one million cells 
were incubated with 100 μl of mAb mixture directed 
against keratin and vimentin containing clones MNF116 
(anti-keratin; IgG1; DAKO), AE1/AE3 (anti-keratin; 
IgG1; Chemicon International Inc, Temecula, CA, 
USA), and V9-2b (anti-vimentin; IgG2b; Department of 
Pathology, LUMC (54)). Next day, cells were incubated 
with 100 μl of premixed FITC and RPE-labeled goat 
F(ab’)2 anti-mouse subclass-specific secondary reagents 
(Southern Biotechnology Associates, Birmingham, AL, 
USA). After washing, cells were incubated with 10 μM 
propidium iodide (PI) and 0.1% DNase-free RNase 
(Sigma). The next day cells were analyzed by flow 
cytometry. A standard FACSCalibur (BD Biosciences, 
Franklin Lakes, NJ, USA) was used for the simultaneous 
measurement of FITC, RPE, and PI. Tumor and normal 
cell populations were flow-sorted using a FACSVantage 
flow-sorter (BD Biosciences) using the FACSCalibur 
filter settings. DNA from flow-sorted material 
was isolated with protease K (0.5 mg/ml) (Roche 
Diagnostics, Basel, Switzerland) in PK-1 buffer solution 
(50 mM KCl, 10 mM Tris (pH 8.3), 2.5 mM MgCl2, 
0.45% NP40, 0.45% Tween 20, and 0.1 mg/ml gelatin) 
with subsequent purification with the Wizard Genomic 
DNA Purification Kit according to manufacturer’s 
instructions (Promega, Madison, WI, USA).
TGFBR2 and ACVR2A fragment analysis in flow-
sorted tumor cells:








ACVR2A microsatellite sequences, primers around 
TGFBR2’s 3rd exon (fw-CCTCGCTTCCAATGAATC, 
rv-TCTGAGAAGATGATGTTGTC), ACVR2A’s 3rd 
exon (fw - GCTTATTTATAGGACTGATTGTG, rv - 
AATCTACAGTTGAGCAAACC) and ACVR2A’s 10th 
exon (fw - TTGAAAGTCAGGAGGATTTTAATG, rv 
- CTAACTGGATAACTTACAGCATG) were designed. 
Forward primers were 5’ labeled with 6-HEX and a 
“linker” sequence (5’-GTTTCTT) was added to the 
reverse primer (55). PCR amplifications were carried 
out with 10 ng of DNA isolated from tumor or stromal 
flow-sorted fractions and 5 pmol of each primer in iQ 
Supermix (Bio-Rad, Hercules CA, USA). Thirty-three 
cycles of amplification with an annealing temperature 
of 60 degrees were performed. PCR products were 
diluted appropriately and mixed in a formamide 
solution containing GeneScan™ 500 ROX™ Size Standard 
(Applied Biosystems, Foster City, CA, USA). Thereafter 
samples were loaded in a 4-capillary 3130 DNA Analyzer 
and results interpreted with the aid of GeneMapper 4.1 
software (Applied Biosystems).
TGF-β pathway reporter transfection and activity 
measurement:
Colorectal cancer cell lines were seeded in 24-well 
plates so that the density at the day of transfection 
was approximately 80%. The cells were transiently 
transfected with 700 ng of the CAGA-luciferase reporter 
construct and 300 ng of the CMV-LacZ expression 
plasmid. For TGFβR2 overexpression in the LS411N 
cells, 300 ng of the CAGA-luciferase reporter construct, 
200 ng of CMV-LacZ and 10ng of TGFBR2 construct 
was used. The cells were transfected using Lipofectamine 
2000 (Life Technologies, Carlsbad, CA, USA) according 
to the manufacturer’s protocol. After 2 days, cells 
were serum starved for eight hours and stimulated for 
sixteen hours with TGF-β3. Lysis and determination of 
luciferase activity were carried out with the Luciferase 
Reporter Assay System according to manufacturer’s 
instructions (Promega, Madison, WI, USA) using 
β-galactosidase activity as an internal control. The 
results are representative of at least three independent 
experiments, and reporter activity is shown as the mean 
and standard error of triplicates.
Generation of TGFβR2 stable knockdowns:
Two TGFβR2 shRNA clones (CCGGGCA-




a control non-targeting shRNA (CCGGCAACAA-
G AT G A A G A G C A C C A A C T C G A G T T G G T -
GCTCTTCATCTTGTTGTTTTTG) from MISSION 
shRNA library (Sigma-Aldrich) inserted in the pLKO.1-
puro lentiviral vector were co-transfected together with 
VSV, GAG/POL and REV lentiviral packaging plasmids 
(kindly provided by Prof. Rob Hoeben, Leiden Universi-
ty Medical Centre) in 293T cells using PEI (MW 25.000 
- Polysciences, Warrington, PA, USA). Forty-eight hours 
after transfection the virus particles were harvested and 
filtered. Colorectal cancer cell lines were seeded at a 
density of 250.000 cells per well in 12-well plates. The 
following day cells were transduced with the lentiviruses 
in a total volume of 1 mL of medium containing DEAE 
and approximately 625.000 IU of virus. Following over-
night incubation the medium was refreshed and two 
days after transduction, selection was performed with 5 
mg/mL of puromycin. From day 14, puromycin concen-
tration was lowered to 2.5 mg/mL. 
Detection of TGF-β ligand binding to type 1, 2 and 3 
TGF-β receptors:
TGF-β ligand was iodinated according to the 
chloramine-T method (56). Affinity cross-linking and 
immunoprecipitation protocols were adapted from a 
previous work (57). Briefly, cells were cultured in 145 
mm dishes to confluency and washed three times with 
a PBS solution containing 0.9 mM of CaCl2, 0.49 mM 
of MgCl2, and 0.1% BSA (PBS+/BSA). Iodinated ligand 
was added to the cells and incubated for three hours on 
ice in PBS+/BSA. Following two washes with PBS+/BSA 
and one with PBS+, crosslinking was induced in the 
presence of 0.27 mM of disuccinimidyl suberate (DSS) 
and 0.07 mM of bis (sulfosuccinimidyl) suberate (BS3) 
in PBS+ during 15 minutes on ice with constant shaking. 
The cross-linking was quenched with detachment buffer 
containing 10 mM Tris-HCl (pH 7.5), 1 mM EDTA, 10% 
glycerol, and 0.3 mM phenylmethylsulfonyl fluoride 
(PMSF) and cells were scraped. Following removal of 
detachment buffer by centrifugation cells were lysed with 
a solubilization buffer containing 125 mM NaCl, 10 mM 
Tris-HCl (pH 7.5), 1 mM EDTA, 1% Triton X-100, 1mM 
PMSF, 2.5 mg/mL Aprotinin and 5 mg/mL Leupeptin 
for 30 minutes on ice. After centrifugation and transfer 
of the supernatants, the cell lysates were incubated 2.5 
hours at 4oC with primary antibodies targeting different 
TGF-β receptors (produced at the Ludwig Institute, 
Uppsala, Sweden). Immunocomplexes were isolated 
by incubating samples with protein A sepharose beads 
for 45 minutes on a rotator. After washing beads four 
times in solubilization buffer the immunocomplexes 
were eluted in SDS sample buffer (125 mM TRIS, 
10% SDS, 20% Glycerol, 10% 2-Mercaptoethanol and 
Bromophenol blue (20 mg/100 mL)), boiled for five 
minutes at 100oC and subjected to SDS-PAGE. Gels 
were dried and scanned with the STORM imaging 
system (Amersham Biosciences).
 
TGFBR2 mutant construct production
TGFBR2 constructs replicating the mutations 
observed in MSI-H colorectal cancers were produced 
and transfected into the TGF-β unresponsive LS411N 
cell line and into COS-1 cells. Constructs containing 
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a (A)9, (A)8 and (A)7 repeat, instead of the wild-type 
(A)10 repeat, were obtained by site-directed mutagenesis 
using the pcDNA3-Myc-TGFBR2 plasmid as template. 
Additional constructs replicating the previous mutations 
at the amino acid level but removing the microsatellite 
repeat by substituting the GAA and AAA codons by 
synonymous GAG and AAG codons respectively were 
also produced. Clone purity was verified by Sanger 
sequencing and mutant fragments were inserted in the 
pcDNA3-Myc-TGFBR2 plasmid by making use of the 
BamH I and Pml I restriction sites.
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Two forms of genomic instability can be 
distinguished in colorectal cancer (CRC) 
tumourigenesis. One is characterised by 
pronounced chromosomal instability 
(CIN), while the other relates to alterations 
produced at the nucleotide level that 
preferentially target microsatellite 
sequences. Tumours developing under 
the latter form of genomic instability 
possess a microsatellite instability-high 
(MSI-H) phenotype due to inactivation 
of the DNA mismatch repair system. The 
most recently described CRC syndrome, 
MUTYH-associated polyposis (MAP), 
shares characteristics with both MSI-H 
and CIN cancers. MAP carcinomas develop 
from the impairment of the base excision 
repair system, where MUTYH is involved, 
but also present a peculiar form of CIN. 
Several clinicopathological characteristics 
of MSI-H and MAP CRCs overlap such as 
tumour location, clinical prognosis and 
histological features. We propose that 
MSI-H and MAP CRCs are particularly 
prone to interact with their tumour 
microenvironment. A great deal of this 
interaction is probably stimulated by the 
immunogenic character of those tumours, 
known to possess a high mutagenic 
potential. The accumulation of mutations 
in coding regions of the genome of MSI-H 
and MAP carcinomas is likely to translate 
into a surplus of neo-antigens that trigger 
an anti-tumour immune response. The 
immune system constitutes thus an 
important vector of selective pressure that 
favours the outgrowth of tumour clones 
with immune-evasive phenotypes. In this 
review, we summarise the evidence for the 
influence of the tumour microenvironment 
in MSI-H and MAP tumourigenesis. 
Furthermore, we discuss how particular 
features of MSI-H and MAP CRCs can 
be exploited for the development of 
therapeutic strategies for affected patients.
INTRODUCTION
Genetic and epigenetic instability 
drives colorectal tumourigenesis (1). Such 
instability derives from the interaction 
between the colorectal epithelium and 
various mutagens like oxidising molecules 
and methylating agents and exposure to 
inflammatory and replicative stress during 
lifetime (2–5). Additionally, the age-related 
decreased functionality of caretaker and 
gatekeeper DNA repair systems diminishes 
the fidelity of DNA replication and indulges 
the accumulation of genetic aberrations in 
cells (6). Genetic and epigenetic alterations 
target, fortuitously, cellular tumour 
suppressor mechanisms and are responsible 
for the generation of tumour clonal 
diversity (7,8). This diversity is essential 
for the selection of the fittest tumour cell 
clones during tumourigenesis (9,10). 
Tumour cells compete against each other 
for growth factors, oxygen and even space. 
Clones that display higher proliferation 
rates and efficient silencing of apoptotic 
mechanisms will be favoured by selection 
(11). Additionally, genetic alterations that 
translate into different metabolic capacities 
will define which tumour clones thrive in 
a specific microenvironment (12). Tumour 
cells must also compete and coexist with 
adjacent non-malignant tissue. Intercellular 
communication comprises an efficient form 
of cellular control that aims to preserve the 
context of multicellularity in the organism 
and impede uncontrolled proliferation of 
altered clones (13). Tumour cells adulterate 
these communication channels by abrogating 
the expression of proteins involved in 
the negative regulation of growth and by 
expressing others that promote survival 
(14). During tumourigenesis, malignant cells 
might even acquire the capacity of partially 
modulating the stimuli provided by non-
malignant tissues (15). Finally, and despite 
the fact that the immune system did not 
evolve to deal with cancer, certain tumours 
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evoke immune responses and introduce an 
additional vector of selective pressure that 
favours the outgrowth of clones possessing 
immune-evasive phenotypes (16,17).
Genetic instability in colorectal 
tumourigenesis mainly occurs in two distinct 
forms. The majority of colorectal cancers 
(CRCs) display pronounced chromosomal 
instability (CIN), including gains and losses 
of large portions of genetic material that 
translate into an aneuploid DNA content 
in tumour cells (18). Approximately 
15% of all CRCs present a microsatellite 
instability-high (MSI-H) phenotype, which 
is characterised by the accumulation of 
mutations in microsatellite sequences, 
a consequence of the inactivation of the 
DNA mismatch repair (MMR) system (19). 
Chromosomal aberrations are relatively 
rare in MSI-H carcinomas and their DNA 
content often remains peri-diploid (20–22). 
In addition to the type of genetic instability 
affecting CIN and MSI-H colorectal 
tumours, certain clinicopathological 
characteristics further define these cancers as 
two different entities (23,24). Another CRC 
variant shares characteristics of both CIN 
and MSI-H tumours. MUTYH-associated 
polyposis (MAP) is an autosomal recessive 
disease caused by inactivation of MUTYH, 
a core protein from the base excision repair 
(BER) machinery (25–27). Despite the fact 
that MAP carcinomas arise in the context 
of a deficiency affecting nucleotide repair, 
MAP tumours display a peculiar type of 
CIN characterised by widespread loss of 
heterozygosity without chromosomal copy 
number alterations (28). It is estimated that 
MAP carcinomas might add up to 1% of all 
CRCs (29).
This review summarises aspects of MSI-H 
and MAP colorectal tumourigenesis that 
support a major role of the microenvironment, 
and particularly the immune system, in the 
development of these tumours. Furthermore, 
we discuss how this interaction can influence 
the management of MSI-H and MAP CRC 
patients.
Aetiology of MSI-H and MAP CRCs
MSI-H CRCs may arise in a sporadic or 
hereditary setting. Sporadic MSI-H tumours 
(12% of all CRCs) develop due to silencing 
of the MLH1 gene by means of promoter 
hypermethylation (30,31). The hereditary 
counterpart of MSI-H CRCs is caused by 
germ line inactivation of a single copy of 
an MMR gene where MLH1, MSH2, MSH6 
and PMS2 are most commonly affected. This 
syndrome, identified as Lynch syndrome, 
manifests in an autosomal dominant 
manner with inactivation of the second 
allele occurring somatically during life (32). 
Some Lynch syndrome cases have also been 
explained by germ line hypermethylation of 
MMR genes and deletions of the 3’ region 
of the EPCAM gene, located upstream of 
MSH2, leading to transcriptional read-
through of the latter (33,34). Lynch syndrome 
accounts for approximately 3% of all CRCs 
and further predisposes for a variety of 
extracolonic tumours (35). The MMR 
caretaker system is responsible for dealing 
with nucleotide mismatches, small insertions 
and deletions. MSH2 and MSH6 form a 
heterodimer responsible for recognising 
mistakes introduced upon DNA replication. 
Thereafter, MLH1 and PMS2 are recruited, 
directing the daughter strand to BER (36). 
Microsatellite sequences are hotspots for the 
establishment of deletions and insertions 
due to the formation of secondary DNA 
structures at these sites during DNA 
replication (37). Thereby, MSI-H tumours 
are easily recognised when comparing the 
sizes of microsatellite sequences between 
tumour and germ line DNA (38).
MAP is caused by germ line inactivation 
of both copies of the MUTYH gene 
(26,27). The MUTYH protein is a BER 
glycosylase, involved in the repair of one 









deoxyguanosine (8-oxoG). 8-OxoG, when 
used as a template, mismatches with adenines 
that can be removed by action of MUTYH. 
When this repair mechanism is impaired, 
the next round of replication results in G:C 
to T:A transversions (25). MAP patients 
normally present, at a young age, an elevated 
number of polyps (between 10 and 100) with 
diagnosis of malignant lesions being made at 
a mean age of 48 years old (29). Whether the 
inherited inactivation of a single copy of the 
MUTYH gene leads to an increased risk for 
cancer is still under debate (39–41).
Clinicopathological features of MSI-H and 
MAP CRCs
Several clinicopathological features of 
MSI-H and MAP carcinomas overlap. One 
of those relates to their location as they are 
often diagnosed at the proximal (right) side 
of the colon (42–45). During embryogenesis, 
the proximal colon (proximal to the splenic 
flexure of the colon) develops from the 
midgut, while the distal colon (distal to the 
splenic flexure) derives from the hindgut. 
These separate embryological origins 
imply distinct blood and lymph supply and 
drainage. For instance, the microvascular 
volume is greater in the proximal colon. 
Additionally, the proximal and distal colons 
are exposed to different dietary and digestive 
constituents, pH conditions and microbial 
flora (23). The preferential location of MSI-H 
and MAP carcinomas in the proximal colon 
suggests that there is a higher demand for the 
intervention of the MMR and BER systems 
in this part of the colon. This could be a 
consequence of an increased exposure of the 
proximal colon to external insults produced 
by chemical agents such as oxidising 
molecules when compared to the distal 
colon. Since the faecal material occurs in a 
liquid form at this stage, it might facilitate 
the interaction of certain mutagens with the 
colon epithelium, thereby inducing DNA 
damage. The colon epithelium is also prone 
to accumulate aberrant DNA methylation 
patterns during lifetime and some loci are 
specifically affected in the proximal colon 
(46,47). CpG island methylation is an 
effective mechanism by which cells either 
silence or activate gene transcription. CpG 
dinucleotides are conserved at promoter 
regions of the genes and hypermethylation 
of the latter usually correlates with decreased 
transcriptional activity and gene silencing 
(48). Virtually, all sporadic MSI-H cancers 
arise with promoter hypermethylation of 
the MLH1 gene, but de novo methylation 
patterns are found throughout their whole 
genome (49,50). Therefore, MSI-H sporadic 
tumours are assumed to possess a methylator 
phenotype (51).
MSI-H and MAP carcinomas also diverge 
from the remaining spectrum of CRC in their 
histological presentation. MSI-H cancers are 
often poorly differentiated and both MSI-H 
and MAP CRCs are often mucinous (24,42). 
Notably, Lynch syndrome carcinomas display 
a less pronounced phenotype when compared 
to sporadic MSI-H tumours (52). The loss of 
the typical colonic crypt architecture implies 
the rearrangement of cell-to-cell interactions, 
favouring the loss of intercellular control 
mechanisms, characteristic of epithelial cells, 
mediated by adhesion molecules such as 
integrins and cadherins (13,53,54). The latter 
molecules are paramount in the perception of 
multicellularity by a cell in an organ context. 
Conversely, the loss of differentiation might 
expose tumour cells to increased interactions 
with the extracellular matrix composed of 
fibroblasts, immune cells, endothelial cells 
and others and moreover, it could favour 
tumour dissemination and invasion to 
adjacent tissues (15).
Genetics of MSI-H and MAP colorectal 
tumourigenesis
CRC genetics is intimately associated 
with the inactivation of the classical 
tumour suppressor Adenomatous Polyposis 
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Coli (APC) gene. Mutations in APC have 
been described to a lower extent in MSI-H 
carcinomas than in the remaining spectrum 
of CRC (42,55). The inactivation of the 
MMR and BER systems in MSI-H and MAP 
cancers is primarily seen as a generator 
of genetic instability and clonal diversity. 
Nevertheless, both DNA repair systems were 
shown to interact with tumour suppressing 
DNA damage response pathways (56,57). 
Accordingly, MMR and BER proteins 
might also function as tumour suppressors. 
Another hallmark of CRC genetics is the 
constitutional activation of the RAS/RAF/
ERK signalling pathway, either by activating 
mutations in the KRAS GTPase or in the 
BRAF kinase. In this aspect, MSI-H and 
MAP carcinomas follow the CRC genetics 
dogma although in distinct manner. MSI-H 
sporadic tumours frequently present V600E 
BRAF activating mutations (in approximately 
half of cases) while those are absent in both 
Lynch syndrome and MAP CRC (58–60). 
These cancers often present mutations in 
the codon 12 of the KRAS gene (59,60). 
MAP tumours are further particularised by 
frequently displaying the characteristic G:C 
to T:A transversions at base position c.34 
(42).
The ‘mutome’ of MSI-H CRCs has been 
described more extensively than the one of 
MAP tumours due to the recent discovery 
of the latter. Genetic research on MSI-H 
CRCs has focused on genes that contain 
microsatellite sequences in their coding 
regions as these are primary targets for 
the establishment of mutations in an 
MMR-deficient background. Accordingly, 
the TGFBR2, IGFR2 and BAX genes are 
frequently affected by frameshift mutations 
in their microsatellite repeats in MSI-H 
colorectal tumours (61–63). The study of the 
TGFBR2 gene assumes particular relevance 
as the TGF-β pathway is considered to play 
a major role in cancer progression (64). 
TGFβR2 is an extracellular receptor that 
mediates the binding of the TGF-β growth 
factors and activation of the intracellular 
SMAD signalling proteins (65). The TGFBR2 
gene possesses a microsatellite repeat of 
10 adenines that is mutated in the majority 
of MSI-H CRCs (62). TGF-β pathway 
activation is generally considered to exert 
tumour suppressive effects, provided by 
growth inhibitory signals, but on the other 
hand, it has also been shown to promote 
tumour growth, angiogenesis, cellular 
plasticity and migration of tumour cells 
(64,66,67). The overgrowth of tumour cell 
clones with inactivating TGFβR2 mutations 
is thought to be associated to the insensitivity 
of those clones to its tumour suppressing 
effects (Figure 1) (68). Conversely, cancer 
cells may increase TGF-β production in 
order to modulate their microenvironment 
and cripple anti-tumour immune responses 
(69,70). Nevertheless, some reports 
suggested that despite the presence of 
inactivating mutations in TGFBR2, MSI-H 
CRC cells might still be sensitive to TGF-β 
growth factors (71,72). Mutations in other 
receptor genes of the TGF-β pathway such 
as ACVR2A and BMPR2 are also common in 
MSI-H cancers (73,74). Although mutations 
in SMAD4 were reported in a minority of 
MAP carcinomas, it is still unknown whether 
and how these tumours target the TGF-β 
pathway (42).
As previously mentioned, the “mutome” 
of MAP carcinomas still remains to be fully 
characterised. Interestingly, MAP carcinomas 
possess a characteristic form of genetic 
instability that differentiates them from 
MSI-H cancers and instead provides them 
with a CIN phenotype. MAP carcinomas often 
exhibit widespread loss of heterozygosity of 
large chromosomal regions without copy 
number alterations, a mechanism referred to 
as copy-neutral loss of heterozygosity (28). 
While loss of heterozygosity is frequent in 
CRCs with CIN, a dominant pattern of copy-
neutral loss of heterozygosity is uncommon 
(75). The high prevalence of this form of 








suggests that homologous recombination is 
a major DNA repair mechanism employed 
by these tumours. MUTYH deficiency could 
thus promote the usage of homologous 
recombination to resolve DNA damage that 
would otherwise be repaired by BER (76).
Immunogenicity of MSI-H and MAP 
colorectal carcinomas
One of the most important characteristics 
of the adaptive immune system relates to 
its ability to distinguish between ‘self ’ and 
‘non-self ’ antigens. This allows the host 
to deal specifically with viral or bacterial 
infections without targeting healthy host 
cells. Theoretically, tumour cells carrying 
a surplus of mutated proteins should be 
dealt with effectively by the immune system 
(77,78). Notwithstanding, during evolution, 
there was no selective pressure for the host 
to deal with cancer as this is an ageing 
disease mostly occurring after reproductive 
age (79). Nevertheless, a strong immune 
reaction, perceived in the form of a dense 
infiltration by activated T lymphocytes, is 
a hallmark of MSI-H CRCs (80,81). Other 
immune cells such as macrophages, dendritic 
cells or neutrophiles are also considered 
to play an important role in MSI-H CRC 
tumourigenesis (82,83). Evidence for an anti-
tumour immune reaction is often detected at 
early stages of tumour development (84,85). 
More recently, MAP carcinomas were also 
shown to possess pronounced infiltration 
by immune cells when compared to other 
microsatellite stable CRCs (42). Moreover 
we, and others, have reported that MSI-H 
and MAP CRCs are particularly prone to 
lose human leukocyte antigen (HLA) class I 
expression (86–89). HLA class I expression, 
in human cells, is essential for competent 
immune surveillance. HLA class I molecules 
can be viewed as cellular informants that 
report to the immune system the mutation 
status of endogenous proteins (90). Antigen 
recognition is primarily mediated by 
CD8+ T cells that become activated in the 
presence of non-self antigens presented in 
an HLA class I context. When a neo-antigen 
is recognised by CD8+ T cells, the latter 
become cytotoxic (cytotoxic CD8+ T cells 
— CTLs) and have the ability to eliminate 
aberrant cells (91). Accordingly, HLA class I 
Figure 1. Diagram representing the clonal evolution 
occurring during MSI-H and MAP colorectal 
tumourigenesis. Clonal diversity is provided by the 
inactivation of the MMR and BER systems (1). A 
genetically heterogeneous population of tumour cells 
is then subjected to selective pressure, exerted by 
the tumour microenvironment (2). The particular 
immunogenic phenotype of MSI-H and MAP CRC 
evokes an immune reaction, mainly mediated by CD8+ 
T cells that favours the outgrowth of tumour cell clones 
that acquired immune-evasive phenotypes. Additionally, 
the desensitization of tumour clones to growth 
suppressive signals derived from the microenvironment 
constitutes a selective advantage (3). 
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loss is interpreted as a mechanism, adopted 
by tumours, to escape immune surveillance 
and thereby avoid tumour cell recognition 
and destruction (Figure 1) (92–94). Both 
MSI-H and MAP CRCs are thought to be 
more capable of triggering an immune 
response as a consequence of the inactivation 
of their respective DNA repair mechanisms. 
As the latter translates in the accumulation of 
mutations in coding regions of their genome, 
the probability that mutated antigens are 
presented to the immune system is higher 
than the one found in CIN CRCs (95). 
Interestingly, distinct molecular mechanisms 
underlie the loss of HLA class I expression 
in sporadic MSI-H and Lynch syndrome 
and MAP CRCs. HLA class I loss was often 
associated with genetic defects in antigen-
processing machinery components in MSI-H 
sporadic tumours, while Lynch syndrome and 
MAP carcinomas frequently failed to express 
β2-microglobulin, the molecular chaperone 
necessary for cell surface expression of HLA 
class I antigens (86,89,96). Approximately 
one-third of MSI-H CRCs were also shown 
to lose HLA-DR expression (97,98). This 
HLA class II molecule is an important 
mediator of antigen presentation in antigen-
presenting cells and its loss could constitute 
an additional immune-evasive mechanism in 
MSI-H CRCs.
The makeup and magnitude of the anti-
tumour immune reaction were previously 
associated with clinical prognosis and 
tumour staging in CRC (99,100). MSI-H 
and MAP tumours have been reported to 
present an improved clinical behaviour when 
compared to the remaining spectrum of 
CRCs (101,102). This observation could be, 
in part, explained by the robust anti-tumour 
immune reaction provoked by these tumours 
(103). Notably, the group from von Knebel 
Doeberitz has reported that healthy Lynch 
carriers are able to mount an antibody-
mediated response against frameshift 
peptides that are commonly mutated in 
MSI-H colorectal tumours (104,105). This 
observation suggests that at some point, 
in the lifetime of Lynch carriers, the host 
immune system encountered those mutated 
peptides. Whether this was also responsible 
for preventing the onset of malignancy is 
still speculative. Paradoxically, the immune 
system, as discussed, is also an important 
vector of selective pressure leading to 
the outgrowth of tumour cell clones with 
immune-evasive phenotypes. Although the 
loss of HLA class I provides tumour cells with 
an effective local adaptation mechanism, it 
might impair tumour migration and tumour 
spreading to other organs (106). A different 
component of the immune system is 
responsible for detecting whether cells carry 
‘self ’ markers such as HLA class I — “missing-
self ” recognition (107). This mission is 
primarily carried out by natural killer (NK) 
cells that become cytotoxic when target cells 
fail to present HLA class I, an inhibitory 
ligand for NK cell activation (108). NK cells 
are mostly present in the blood stream and 
thus do not affect local tumour growth but 
when tumour cells metastasise they might 
encounter NK cells and be eliminated 
(109). It is thought that tumour cells often 
compensate HLA class I loss by favouring 
the expression of additional NK-inactivating 
ligands and by losing antagonist ligands 
with NK-activating properties (110,111). 
We found a significant association between 
the presence of activated CD8+ T cells in 
Lynch carcinomas and early staging of the 
primary tumours. Conversely, we discovered 
an elusive immune cell population that is 
characteristic for non-metastasised Lynch 
CRCs (N. de Miranda, in preparation). Such 
complementary immune reaction by two 
types of immune cells countering tumour 
growth locally and at distance might explain 
the improved clinical prognosis of Lynch 
CRC patients and be further explored for 








Management of MSI-H and MAP CRC 
patients
As discussed, MSI-H and MAP colorectal 
patients are thought to possess improved 
survival rates when compared to the 
remaining spectrum of CRC patients 
(101,102). This observation could be partly 
explained by the immunogenic character 
of MSI-H and MAP tumours. On the 
other hand, their DNA repair-deficient 
background could be responsible for the 
frequent generation of unviable tumour 
clones that have reached unsustainable states 
of genomic instability (103). Nevertheless, 
MSI-H CRC patients do not seem to 
benefit from adjuvant fluorouracil (5-
FU) chemotherapy, which integrates the 
chemotherapeutic scheme (also including 
oxaliplatin) generally applicable to Stages III 
and IV CRCs (112,113). Additionally, still 
a considerable amount of MSI-H patients 
present advanced tumour stages at diagnosis 
and succumb from this disease. Therefore, 
novel therapeutic strategies that specifically 
target this group of tumours should be 
developed and their rationale could also be 
applied to the treatment of MAP carcinomas.
The immunogenic character of MSI-H 
and MAP carcinomas remains to be fully 
exploited and might hold a promising source 
of therapeutic opportunities. Vaccination and 
T cell-based immunotherapeutic approaches 
provide a way to prolong survival of certain 
groups of patients in clinical trials but 
treatment of advanced disease still remains a 
promise (114). This may be explained 2-fold: 
as demonstrated, advanced CRCs already 
acquired immune-evasive phenotypes and 
are therefore insensitive to therapeutic 
vectors that require antigen recognition, 
and the intrinsic nature of the clinical trials 
does not allow the selection of patients with 
cancers that present immunogenic features. 
The findings from von Knebel Doeberitz’s 
group (104,105) have encouraged others 
to propose the application of prophylactic 
vaccination strategies in Lynch syndrome 
and MAP patients. The stimulation of an early 
and robust response of the immune system, 
based on commonly mutated peptides, could 
prevent or delay tumour onset at a stage that 
antigen presentation still occurs in cancer 
cells. From the diagnostic point of view, the 
monitoring of serum responses to tumour 
antigens could be utilised for improved 
surveillance of Lynch and MAP carriers. On 
the other hand, the recruitment of Lynch and 
MAP patients for such trials is difficult as they 
are already included in effective colonoscopic 
surveillance schemes (115,116).
The DNA repair-deficient background 
of MSI-H and MAP colorectal carcinomas 
might also encourage the investigation of the 
efficacy of targeting DNA repair mechanisms 
based on the concept of synthetic lethality 
(117). MMR and BER mechanisms 
cooperate in the processing of mutations and 
the targeting of one system in the genetic 
background of deficiency of the other could 
promote the generation of an unsustainable 
state of genetic instability in tumour cells. 
Our group reported the extremely mild 
phenotype of a Lynch patient that in addition 
to possessing a germ line MSH6 mutation 
was also carrier of compound heterozygous 
mutations in the MUTYH gene. A genetic 
background of synthetic lethality that 
impedes the establishment of a second hit 
in the MSH6 gene when BER is inactivated 
might offer an explanation for this mild 
phenotype (118).
Future perspectives
With the current advances in genomic 
technology, we are expected to comprehend 
further the genetics of MSI-H and MAP CRC 
tumourigenesis. Moreover, the definition of 
the landscape of the cancer genome of these 
tumours might deliver novel therapeutic 
targets, including the definition of a set of 
commonly mutated antigens that could 
be used for prophylactic vaccination of 
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Lynch syndrome and MAP carriers. The 
description of mutations in MSI-H CRCs has 
been strongly biased towards microsatellite 
repeats as their screening is less technically 
demanding and strongly supported by the 
type of DNA repair deficiency characteristic 
of MSI-H tumours. Nevertheless, since the 
processing of nucleotide mismatches in an 
MMR-deficient background is also impaired, 
a surplus of this type of mutations is also 
expected to be found in MSI-H cancers. 
Mismatches that translate into amino 
acid substitutions could be more easily 
applicable for vaccination strategies as they 
are less likely to affect protein expression 
as opposed to frame shifts that introduce 
early STOP codons and affect mRNA and 
protein stability. The definition of common 
mutation targets in MAP carcinomas 
would simultaneously shed light on the 
genetics of tumourigenesis of these cancers 
and provide potential therapeutic targets. 
In the meanwhile, the high frequency of 
G:T transversions observed in codon 12 of 
the KRAS gene could be exploited for the 
testing serum responses in MAP patients 
against KRAS mutated peptides. Finally, the 
close association between MSI-H and MAP 
tumour progression with the loss of HLA 
class I expression suggests that individuals 
might be at a different risk for developing 
CRC depending on their ability to present 
tumour antigens to the immune system. The 
extremely polymorphic character of the HLA 
class I system and variation of haplotypes 
among the population might conceal distinct 
susceptibilities to the development of these 
diseases.
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CONCLUDING REMARKS AND 
FUTURE PERSPECTIVES
MSI-H and MAP cancers are now 
recognized as well defined entities within 
the spectrum of colorectal malignancies. 
The high prevalence of immune escape 
mechanisms observed in those, particularly 
the widespread loss of HLA class I 
expression, conceals important clinical 
implications. Defects in the HLA class I/
antigen presenting pathway will most likely 
frustrate immunotherapeutic interventions 
that require T cell recognition of tumor 
antigens. Although it has been shown that 
HLA class I expression can be induced in 
cancer cells (1), this is unlikely to occur when 
genetic defects such as mutations in the β2m 
molecule are present. Nevertheless, passive 
immunotherapeutic approaches based on 
the production of antibodies against tumor 
antigens remain valid (2). 
The outgrowth of tumor cell clones with 
HLA class I defects is secondary to the 
elimination of cancer cells that effectively 
presented HLA class I/antigen complexes 
to T cells. Thus, theoretically, the complete 
eradication of tumors might occur in the 
presence of a robust immune reaction at 
early stages of malignancy. Two working 
hypothesis can be derived from this 
proposition:
1. Prophylactic approaches based on the 
vaccination of individuals with common 
tumor antigens may be developed, especially 
in the context of cancer syndromes such as 
Lynch or MAP. These could elicit potent 
secondary anti-tumor immune responses 
shortly after tumor initiation and prior to the 
generation of immune escape phenotypes. 
In support of this, Schwitalle and colleagues 
have detected T cell-mediated responses in 
healthy Lynch syndrome carriers against 
mutated tumor-antigens that are commonly 
generated in MSI-H colorectal cancers 
(3). Such observation suggests a previous 
interaction between the host immune system 
and malignant cells in spite of the lack of a 
cancer diagnosis. Of note, the generation of 
mutated antigens in tumor cells must occur 
before the loss of HLA class I expression 
for the successfulness of this approach. 
Therefore, the elucidation of the sequential 
ordering of oncogenic events in Lynch or 
MAP cancers is of great importance.
2. Considering the specificity exhibited by 
different HLA class I molecules to different 
peptide motifs, one expects that certain 
alleles are more efficient than others in 
presenting certain tumor antigens. Several 
logical inferences can be derived from 
this premise: a) In a carrier of HLA class I 
alleles with poor tumor antigen presentation 
capability, the immune system might be more 
permissive to the development of MSI-H and 
MAP tumors; b) In the same context, tumors 
can conserve HLA class I expression due to 
the lack of selective pressure against HLA 
class I positive tumors; c) conversely, the 
immune system of carriers of HLA class I 
alleles that effectively present tumor antigens 
might be less tolerant to tumor development; 
d) accordingly, HLA class I-related immune 
escape phenotypes would be more likely in 
the latter. To establish whether HLA class I 
genotypes influence the risk for colorectal 
cancer development, particularly for MSI-H 
and MAP cancers, comprehensive large-scale 
association studies, focused on HLA class I, 
are required. The incomplete penetrance 
observed in Lynch syndrome (4) could 
also be related to the capacity of the host’s 
immune system to deal with tumor cells.
It is now well recognized that the presence 
of a conspicuous adaptive immune response 
can influence tumor development and 
clinical outcomes. The infiltration of tumor 
tissues by CD8+ cytotoxic T cells (CTLs) has 
been consistently correlated with improved 
patient prognosis in a variety of cancers, 
including colorectal cancer (5, 6). In this 
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thesis, we present a similar observation 
made in Lynch colorectal cancers where 
higher densities of CTLs were found in early-
staged tumors. Remarkably, the presence of 
an elusive immune cell population (CD45+/
CD3-/CD56-/GZMB+) was highly predictive 
of a tumor HLA class I negative phenotype 
and of the absence of lymph node metastases. 
Unfortunately, despite the employment of 
numerous markers, we did not succeed in 
gaining further insight into the phenotype 
of these cells. The fact the latter were almost 
exclusively found in HLA class I negative 
tumors and that they might be involved in 
counteracting metastatic processes suggests 
a mode of action similar to the one of NK 
cells. Their characterization might open new 
possibilities for the management of tumors 
that have lost HLA class I expression. Our 
findings demand for additional investigation 
in MSI-H sporadic and MAP colorectal 
cancers, as well as in other cancer types, 
to establish the role of these cells in tumor 
progression. The improved clinical prognosis 
observed for MSI-H colorectal patients is 
likely to be associated with the immunogenic 
character of their tumors. Although the 
capacity of MSI-H and MAP cancers to evade 
immune responses is well demonstrated by 
their HLA class I phenotypes, this form of 
“local adaptation” might not be optimal once 
tumor cells enter circulation and encounter 
other components of the immune system. 
Nevertheless, a considerable proportion of 
MAP and MSI-H tumors do metastasize 
and the complexity of tumor/immune 
cell interaction transcends HLA class 
I-dependent immune responses. 
The mismatch repair deficiency observed 
in MSI-H cancers determines that a number 
of gene targets are consistently mutated in 
these tumors. Until now, it was believed that 
the occurrence of microsatellite instability 
within coding genetic sequences led to 
abrogation of expression of their respective 
proteins. We discovered that frameshift, 
truncating mutations in TGFBR2 gene did not 
hinder the generation of functional, in-frame 
proteins. We hypothesized that the reversal 
of the TGFBR2 mutated sequence to a wild 
type form may occur at the transcriptional 
level, by similar mechanisms that degenerate 
in DNA microsatellite instability. A similar 
observation was previously made for a 
mutant human apolipoprotein B (APOB) 
allele that causes hypobetalipoproteinemia 
(7). Although colorectal cancer cells can 
theoretically mutate TGFBR2 to a form that 
is not prone to transcriptional instability, a 
positive selection appears to be in place for 
a genotype that permits the production of 
functional TGFβR2. This might reflect some 
TGF-β dependence of tumor cells that could 
be exploited from a therapeutic perspective. 
With the current knowledge in hand, the 
effects of TGF-β activation and inhibition in 
TGFBR2-mutated cells should be analyzed 
in depth. Additionally, the “leakiness” of 
frameshift mutations in other mutation 
targets should also be investigated in MSI-H 
cancers.
The reversal of mutated microsatellite 
sequences to wild-type sequences at the 
transcriptional level suggests that the 
generation of “frameshifted” transcripts from 
wild-type DNA sequences also occurs. This 
raises a fundamental question that transcends 
the context of cancer research: why were 
microsatellite sequences located in coding 
DNA sequences conserved during evolution? 
The generation of more stable, synonymous 
sequences could easily be achieved by the 
random substitution of the last nucleotide 
of a codon that composes a microsatellite. 
Curiously, for TGFBR2, the opposite is 
observed by comparative genomics: only 
few primates, including humans, display a 
microsatellite sequence of 10 adenines in 
TGFBR2 while other mammals have an 8 
or 7 adenines microsatellite, resulting in 
a considerably more stable sequence. In 
bacteria, it has been established that the 
conservation of these homopolymeric tracts 








However, those are normally located in 
frameshifted genes that generate in-frame 
sequences during transcription (8). The 
role of microsatellite sequences located in 
genes that are already in-frame is less clear, 
but might relate to intrinsic gene regulation 
mechanisms that impede the generation of 
elevated amounts of functional transcripts in 
a particular context.
Mismatch and base excision repair defi-
cient colorectal cancers constitute fascinat-
ing models of cancer evolution. Their intrin-
sic DNA repair defects provide a source of 
genetic diversity that, in the case of MSI-H 
cancers, dispenses major chromosomal al-
terations. Their mutagenic character, how-
ever, comes with drawbacks: their extensive 
mutation landscape implicates an abundance 
of tumor antigens that elicit anti-tumor im-
mune responses. The latter actively partici-
pate in the process of tumor clonal selection 
that favors the outgrowth of cancer clones 
with immune evasive phenotypes. The im-
portant role of the immune system in shaping 
the evolution of MSI-H and MAP colorectal 
cancers should not be ignored and could be 
explored for the development of prophylactic 
and therapeutic approaches.
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The works presented in this thesis have focused on the study of specific subtypes of 
colorectal cancer that arise in a context of deficiency of one of the following DNA repair 
systems: mismatch repair or base excision repair. Colorectal cancer is one of the most 
common and deadliest cancers in the world. It is a heterogeneous disease that comprises 
a range of malignancies that develop according to various genetic/oncogenic pathways. 
DNA mismatch repair deficient cancers comprise up to 20% of all colorectal cancers and 
are characterized for exhibiting a microsatellite instability-high (MSI-H) phenotype. The 
latter refers to the widespread accumulation of small insertions and deletions at microsatellite 
sequences, throughout the genome. MSI-H colorectal cancers can develop sporadically or 
due to hereditary mutations in one of the mismatch repair genes (Lynch syndrome). Base 
excision repair deficient colorectal cancers are caused by hereditary mutations in the MUTYH 
gene. Carriers of biallelic mutations in MUTYH are at increased risk of developing colorectal 
polyps and cancer and this syndrome is referred to as MUTYH-associated polyposis (MAP). 
MAP cancers constitute less than 1% of all diagnosed colorectal cancers.
MSI-H colorectal cancers often carry more mutations in their coding genome than the 
remaining subtypes of colorectal cancer, a consequence of their constitutive DNA repair 
deficiency. As mutations eventually translate to the protein level, abnormal proteins are 
generated that can be recognized by the immune system. Effector immune cells, such as 
cytotoxic CD8+ T cells, have the capacity of eliminating cancer cells that present such proteins 
and, therefore, tumors must adopt mechanisms that allow them to escape destruction. 
Among those mechanisms, one of the most important is the loss of expression of HLA class 
I, the molecule responsible for presenting endogenous peptides to cytotoxic CD8+ T cells. 
Although the loss of HLA class I expression was previously described as a common event 
during colorectal carcinogenesis, we and others hypothesized that it was more likely to occur 
in MSI-H tumors due to their hypermutated genomes. Additionally, MSI-H cancers are 
notable for presenting a conspicuous immune cell infiltrate in their tissues which reflects a 
strong anti-tumor immune reaction. Accordingly, in chapter 2, we describe that HLA class 
I alterations are clearly more frequent in MSI-H tumors than in the remaining spectrum of 
colorectal malignancies. 
Loss of expression of HLA class I can occur through a number of mechanisms that include 
mutations in the HLA class I genes themselves, mutations in the gene encoding for the β 
chain (β2m), and mutations in molecules that are involved in the processing of the proteins 
to be loaded on HLA class I, denominated by antigen processing machinery. Also in the work 
included in chapter 2 we discovered that HLA class I loss was more likely to be associated with 
deficiencies in members of the antigen processing machinery in sporadic MSI-H cancers than 
in their hereditary counterpart. Conversely, MSI-H tumors from Lynch syndrome patients 
were most often affected by deficiencies in the β2m molecule. It is known that deficiencies in 
β2m or in antigen processing machinery members have different consequences but the reason 
why sporadic and hereditary MSI-H cancers target one or the other are still elusive.
Although it was not yet established whether MAP colorectal cancers carry a higher 
number of mutations than non-MSI-H colorectal tumors, we considered it to be a logical 
assumption due to their background of base excision repair deficiency. MAP cancers also 
present evidence for an anti-tumor immune reaction which suggests that, similar to MSI-H 
cancers, these tumors are also strongly immunogenic. In such case, a strong selective pressure 








place. In the work presented in chapter 3, we describe that HLA class I loss of expression is 
indeed a frequent event in MAP colorectal cancers. Interestingly, and as observed for Lynch 
syndrome cancers, loss of HLA class I expression was most often associated with β2m defects, 
which appears to be a common mechanism in MAP and Lynch colorectal syndromes. With 
this work we completed the characterization of HLA class I phenotypes in colorectal cancers 
that arise in a context of DNA repair deficiency. We concluded that such deficiency is likely 
to be responsible for the generation of a surplus of mutated proteins in tumors, which in turn 
activates an immune response that favors the outgrowth of tumor clones with immune escape 
phenotypes.
Assuming that the quality and intensity of an anti-tumor immune response influences the 
HLA class I phenotype of tumors, we investigated whether this relation could be observed 
in Lynch colorectal cancers, in chapter 4. Indeed we found that cancers carrying HLA class 
I defects presented higher amounts of tumor-infiltrating lymphocytes, particularly CD4+ 
and CD8+ T cells. This observation provides a link between the agents of selective pressure 
(immune cells) and the positively selected tumor traits (loss of HLA class I expression). 
Furthermore, the magnitude of lymphocytic infiltration not only correlated with HLA class 
I phenotypes but also with the tumor stage at diagnosis. Infiltration by activated CD8+ T 
cells (cytotoxic T cells) was higher in tumors diagnosed at early stages than in advanced 
cancers, supporting the anti-tumorigenic role of these cells. An elusive immune cell type 
that expressed granzyme B, thus with cytotoxic potential, was almost exclusively present in 
HLA class I negative tumors that lacked metastases. These characteristics were reminiscent 
of NK cells but further investigation with a range of discriminative immune cell markers was 
inconclusive. The identification of these cells could be of great importance of the management 
of cancers that have lost HLA class I expression.
In chapter 5, we present a study on the most frequently mutated gene in MSI-H cancers, 
TGFBR2. Until now, mutations in TGFBR2 were considered to result in loss of protein function 
due to the frameshift, truncating nature of the mutations found. We discovered that cells 
carrying biallelic, frameshift mutations in TGFBR2 were still capable of transducing TGF-β 
signaling in a TGFβR2-dependent manner. We proposed that the same mechanism that leads 
to the generation of mutations at the DNA level is probably responsible for the restoration 
of TGFBR2’s reading frame at the transcriptional level. Thus, frameshift mutations located 
at microsatellite sequences have the potential to be reversed to a wild type form at the RNA 
level. Interestingly, we discovered that MSI-H cancers were apparently selected to retain some 
sensitivity to TGF-β since the occurrence of biallelic mutations that excluded the possibility 
of reading frame restoration was rare. We suggest that the contribution of this pathway for the 
tumorigenesis of MSI-H tumors should be reanalyzed in the light of these findings.
In chapter 6, we review our findings on MSI-H and MAP tumors in the light of others’ 
findings and propose that the oncogenic processes in these cancers are particularly dependent 
on the interaction between the tumor cells and their microenvironment. In chapter 7, some 









In dit proefschrift werden twee subtypes van kanker in de dikke darm bestudeerd, die 
ontstaan in de context van twee DNA reparatie defecten, te weten een DNA mismatch 
reparatie deficientie en een DNA base excisie reparatie defect. Dikke darm kanker is een veel 
voorkomende en een van de dodelijkste ziekten in de wereld. Hoewel de naam eenduidig lijkt, 
is dikke darm kanker genetisch een heterogene ziekte. Twintig procent van alle dikke darm 
tumoren tonen een DNA mismatch reparatie deficiente. Ten gevolge van deze deficientie 
worden veel voorkomende secundaire fouten (mutaties) in het DNA, die vooral ontstaan 
tijdens de celdeling, niet meer goed herkend en hersteld. De aanwezigheid van de secundair 
ontstane mutaties in zich herhalende DNA patronen kunnen worden getest middels een 
“microsatelliet instabiliteits” analyse, waarbij een “MSI-High” fenotype een aanduiding is van 
een DNA mismatch reparatie defect. MSI-H kan sporadisch ontstaan of gevonden worden 
in de context van erfelijke mutaties in een van de mismatch reparatie genen, passend bij het 
Lynch syndroom. Mensen die zowel van hun moeder als vader een mild defect in het DNA 
base excisie reparatie gen MUTYH hebben georven, ontwikkelen meestal veel poliepen in de 
dikke darm en hebben dien ten gevolge een verhoogde kans op dikke darm kanker. Dikke 
darm kanker in de context van deze MUTYH geassocieerde polyposis (MAP) betreft minder 
dan 1% van alle gediagnosticeerde dikke darm kankers.
Bij microscopisch onderzoek van DNA mismatch en in mindere mate DNA base reparatie 
deficientie wordt vaak een opvallende influx van tumor infiltrerende lymfocyten (TIL’s) 
gezien. Dit kan worden verklaard door een verhoogde respons van het immuunsysteem 
(de afweer) op gemuteerde tumor eiwit fragmenten, die ontstonden ten gevolge van de 
secundair ontstane DNA mutaties. De afweer reactie zou zelfs de tumor kunnen opruimen, 
waardoor de tumor mechanismen moet ontwikkelen om deze afweer te ontlopen. Inderdaad 
toonden met name de genoemde DNA reparatie deficiente tumoren een verhoogde mate van 
afschakeling van HLA (humane leucocyten antigeen) klasse I moleculen. HLA moleculen 
zijn betrokken bij het presenteren van lichaamseigen en lichaamsvreemde eiwitdelen 
(waaronder tumoreiwitdelen) aan de afweer. We toonden aan dat het verlies van HLA klasse 
I in dikke darm tumoren van Lynch en MAP patienten ontstaat middels mutaties in het 
beta2microglobuline gen. Daarentegen de niet erfelijke vorm van DNA reparatie deficient 
dikke darmkanker weet hetzelfde te bereiken door afschakeling van componenten van de 
antigeen presenterende machinerie (APM). Waarom er zo’n duidelijke scheiding binnen de 
subgroepen is onduidelijk, doch intrigerend. 
Vervolgens werd in een relatief grote subgroep van Lynch syndroom dikke darm kankers 
onderzocht of er een relatie bestaat tussen de aanwezigheid en de hoeveelheid TIL’s, hun 
subtypering en het HLA expressie verlies. Tevens werd de relatie onderzocht met het stadium 
van de ziekte. In tumoren met HLA klasse I verlies werden grotere hoeveelheden geactiveerde 
TIL’s gevonden, alsof deze tumoren onder selectieve druk stonden tumor subklonen te 
genereren die de afweer reactie konden ontlopen. Een grotere mate van TIL’s werd gevonden 
in vroegere vergeleken met latere tumor stadia, hetgeen een anti-tumorigene rol van deze 
TIL’s doet vermoeden. Vervolgens werd ook een geactiveerde immuun cel gevonden met 
kenmerken van een zogenaamde “natural killer” cel. Uitgebreide marker analyse van deze cel 
leidde niet tot preciese karakterisering van dit celtype. De aanwezigheid van deze geactiveerde 
immuuncel bleek te correleren met de afwezigheid van tumor uitzaaiingen.  
Daarnaast werd het meest frequent gemuteerde gen in MSI-H tumoren,TGF-β, bestudeerd. 
Tot nu toe werd aangenomen dat mutaties in dat gen resulteerden in het verlies van 
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eiwitfunctie door de frameshift mutaties die gevonden werden. Er werd ondekt dat cellen 
met een biallelische frameshift mutatie in TGFBR2 nog in staat zijn om TGF-β signalen door 
te geven. Er werd verondersteld dat hetzelfde mechanisme dat leidt tot DNA mutaties ook 
verantwoordelijk is voor het herstel van veranderingen in TGFBR2 op transcriptieniveau. Het 
interessante is dat MSI-H tumoren nog enige mate van TGF-β gevoeligheid bleken te hebben 
gezien het voorkomen van bialelische mutaties zonder frameshift reparatiemechanisme 
zeldzaam zijn. In het licht van de bovengenoemde bevindingen zal het heersende beeld over 
de rol van het TGF-β signaalroute in de tumorigenese van MSI-H tumoren herzien moeten 
worden.
Voorts werden de bevindingen aangaande MSI-H en MAP tumoren in het licht van 
andere onderzoeksresultaten geplaatst en werd voorgesteld dat de oncogene processen in 
deze tumoren voornamelijk afhankelijk zijn van de interactie van de tumor cellen met hun 
micromilieu. Tenslotte werd een aantal sugesties gedaan tot het voortzetten van dit onderzoek.
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